

# Membrane protein folding, misfolding, and quality control

Eojin Kim<sup>1</sup>, Seoyoon Kim<sup>1</sup>, Minseung Kim<sup>1</sup>, and Duyoung Min, Department of Chemistry, Ulsan National Institute of Science and Technology, Ulsan, Republic of Korea

© 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

This is an update of S.K. Buchanan, S. Yamashita, K.G. Fleming, 5.8 Structure and Folding of Outer Membrane Proteins, Editor(s): Edward H. Egelman, Comprehensive Biophysics, Elsevier, 2012, Pages 139–163, ISBN 9780080957180, <https://doi.org/10.1016/B978-0-12-374920-8.00514-2>.

Introduction	1
Membrane protein biogenesis and quality control	2
Physicochemical principles of membrane protein folding	5
Membrane protein misfolding and therapeutic approaches	7
Outlook	11
Acknowledgments	12
References	12

## Key points

- Summarize the major cellular pathways that govern membrane protein biogenesis, including co-translational insertion and early quality-control mechanisms.
- Describe the physicochemical principles underlying the folding of  $\alpha$ -helical bundles and  $\beta$ -barrels within lipid bilayers.
- Discuss how misfolding of membrane proteins and failures in proteostasis contribute to human diseases.
- Outline therapeutic strategies aimed at rescuing or selectively degrading misfolded membrane proteins, including pharmacological chaperones and targeted degraders.

## Abstract

Membrane proteins represent nearly one-third of the cellular proteome and carry out essential functions in signaling, transport, and energy conversion. This chapter summarizes key aspects of membrane protein folding and biogenesis, including co-translational insertion, quality-control systems, folding mechanisms, and misfolding-related diseases. We also outline emerging therapeutic strategies aimed at rescuing or selectively degrading misfolded membrane proteins.

## Introduction

Membrane proteins perform many of the most essential tasks in living systems (Li et al., 2021). They sense and transmit extracellular signals into intracellular responses through receptors such as G protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs); regulate the passage of ions and metabolites across otherwise impermeable lipid bilayers through channels, transporters, and pumps; drive energy capture and conversion in respiratory and photosynthetic pathways; and provide scaffolding for cell-cell and cell-matrix interactions. Across organisms, approximately 20–30% of proteins are membrane-associated, highlighting the evolutionary commitment to this protein class (Dobson et al., 2023; Almén et al., 2009; Krogh et al., 2001; Wallin and von Heijne, 1998).

The biomedical significance of membrane proteins is equally striking. More than half of approved drugs target membrane proteins—most notably GPCRs, ion channels, and transporters—because these proteins are both readily accessible to pharmacological agents and central to physiological control (Santos et al., 2017). Moreover, membrane protein misfolding or dysregulation contributes to diverse human diseases, including neurodegeneration, cardiac arrhythmias, metabolic disorders, cystic fibrosis, and cancer (Marinko et al., 2019; Liu and Dudley, 2018; Fraser-Pitt and O’Neil, 2015). Beyond their pharmacological importance, engineered membrane proteins and membrane-mimetic platforms are driving new frontiers in biosensing, synthetic biology, and nanotechnology (Meyer et al., 2025; Selivanovitch et al., 2024; Arya et al., 2023). Therefore, elucidating how membrane proteins fold—how they establish correct topology, pack  $\alpha$ -helices or  $\beta$ -strands, assemble into functional oligomers, and remain stable within a dynamic lipid bilayer—is fundamental to both basic biology and translational research.

<sup>1</sup>These authors contributed equally to this work.

Conceptual foundations of the field were laid by early models of membrane organization. The lipid bilayer concept established the membrane's structural basis, while the fluid-mosaic framework highlighted its dynamic nature and the central role of embedded proteins (Nicolson and de Mattos, 2022; Nicolson, 2014; Singer and Nicolson, 1972). Pioneering studies in the late 20th century led to the two-stage model for  $\alpha$ -helical membrane proteins: first, transmembrane (TM) helices insert into the bilayer, and then they laterally pack and assemble into a functional fold (Popot and Engelman, 1990; Engelman et al., 2003; MacKenzie, 2006). In cells, however, the process is more intricate. In bacteria and in the eukaryotic endoplasmic reticulum (ER), most  $\alpha$ -helical membrane proteins are inserted co-translationally through the Sec translocon, assisted by YidC/Oxa1-superfamily insertases, which facilitate proper insertion and reduce the risk of misfolding (Hegde and Keenan, 2024; Cymer et al., 2015; Osborne et al., 2005). Meanwhile, studies in Gram-negative bacteria revealed distinct pathways for  $\beta$ -barrel outer-membrane proteins (OMPs): these substrates are escorted across the periplasm by chaperones such as SurA and Skp, and then inserted and folded by the  $\beta$ -barrel assembly machinery (BAM) complex (Noinaj et al., 2013, 2015, 2017; Hagan et al., 2011; Sklar et al., 2007).

The lipid bilayer is an anisotropic and heterogeneous environment, characterized by a thin apolar core, steep polarity gradients, and lateral pressure profiles (Corin and Bowie, 2020; Ding et al., 2015; White and Wimley, 1999; Cantor, 1999). As a result, membrane protein folding entails partitioning between aqueous and hydrophobic phases, conforming to topological constraints (such as inside-outside asymmetry), and coupling strongly to bilayer mechanics, including thickness, curvature, and tension (Machin et al., 2023; Renne and Ernst, 2023; Corin and Bowie, 2020). Membrane composition further modulates folding stability and pathways: factors such as headgroup charge, acyl-chain saturation, sterol content (e.g., cholesterol), and hydrophobic mismatch influence helix packing and oligomerization equilibria (Peruzzi et al., 2024; Machin et al., 2023; Corin and Bowie, 2020; Muller et al., 2019). Moreover, certain proteins rely on specific lipid interactions, such as cardiolipin binding in bacterial and mitochondrial transporters (Senoo et al., 2024; Laganowsky et al., 2014; Hunte, 2005).


Membrane-mimetic systems—including supported bilayers, vesicles, nanodiscs, and bicelles—approximate native environments (Harris et al., 2022; Notti and Walz, 2022), but can sometimes destabilize the folded state or bias folding pathways. Nevertheless, the field advanced from early denaturant-induced (un)folding studies to denaturant-free approaches, such as the steric trapping method, which enabled detailed analysis of model systems, including bacteriorhodopsin and the rhomboid protease GlpG (Kim et al., 2025; Wijesinghe and Min, 2023; Hong et al., 2009). Membrane protein folding kinetics were further refined through single-molecule force spectroscopy methods, such as magnetic tweezers, which directly resolved folding steps and intermediate lifetimes, and enabled quantitative estimation of barrier heights (Wijesinghe and Min, 2023).

This chapter provides a concise overview of key aspects of membrane protein folding and biogenesis, and highlights how this knowledge informs therapeutic strategies. **Membrane protein biogenesis and quality control** section describes co-translational insertion and quality-control systems in bacteria and the eukaryotic ER that coordinate topology and prevent early misfolding. **Physicochemical principles of membrane protein folding** section examines the physicochemical principles that govern the energetics, kinetics, and pathways of  $\alpha$ -helical and  $\beta$ -barrel membrane proteins within lipid bilayers. **Membrane protein misfolding and therapeutic approaches** section considers how perturbations in these processes give rise to misfolding-related diseases and discusses emerging pharmacological and proteostasis-based interventions aimed at restoring balance.

## Membrane protein biogenesis and quality control

For many  $\alpha$ -helical membrane proteins, folding begins co-translationally, while synthesis is still ongoing (Min, 2024). As hydrophobic segments emerge from the ribosome, the signal recognition particle (SRP) captures the ribosome-nascent chain complex (RNC) and delivers it to the protein-conducting channel: SecYEG in bacteria or Sec61 in the eukaryotic ER (Fig. 1A) (Sánchez et al., 2025; Hegde and Keenan, 2022). Once engaged, translation resumes, and the nascent chain is threaded into the channel, which features a lateral gate that opens into the lipid bilayer (Figs. 1A and 2) (Lewis et al., 2024; Ge et al., 2014). TM segments partition laterally according to their hydrophobicity and flanking charges, establishing membrane protein topology consistent with the positive-inside rule, while folding and glycosylation of soluble domains further stabilize and refine TM orientation (Duart et al., 2024; Janoschke et al., 2021; von Heijne, 2006; van den Berg et al., 2004). Because elongation of the polypeptide chain is coupled to membrane insertion, factors such as codon usage, translation rate, and the sequential emergence of charged or reentrant segments can bias topological outcomes, thereby imprinting constraints that influence subsequent folding (Nicolaus et al., 2021; Pechmann et al., 2014).


Alternative insertases provide additional routes for membrane protein insertion (Figs. 1A and 2). In bacteria, YidC facilitates the integration of single-pass proteins or individual TM segments from multipass proteins by providing a hydrophilic groove and locally thinning the bilayer (Caliseki et al., 2025; Dalbey et al., 2023; Kim and Min, 2023; Chen et al., 2017). Its homologs, Oxa1 in mitochondria and Alb3 in chloroplasts, carry out analogous insertase functions (Wang and Dalbey, 2011). In the ER, the ER membrane protein complex (EMC) lowers the energetic barrier for marginally hydrophobic or tilted helices and often cooperates with Sec61 to ensure productive assembly of multipass topologies (Fig. 2) (Klose et al., 2025; Wu et al., 2024; Pleiner et al., 2020; Chitwood and Hegde, 2019; Chitwood et al., 2018). Tail-anchored proteins, whose C-terminal TM domain emerges only after translation terminates, are delivered post-translationally via the GET pathway in yeast or the TRC pathway in mammals, with EMC contributing to insertion in certain cases (Farkas and Bohnsack, 2021; Hegde and Keenan, 2011). Electrochemical gradients across membranes—comprising both membrane potential and proton concentration differences—further bias the insertion of charged



**Fig. 1** Biogenesis of  $\alpha$ -helical and  $\beta$ -barrel membrane proteins in cells. (A) Biogenesis of  $\alpha$ -helical membrane proteins. Signal recognition particle (SRP) directs ribosome-nascent chain complexes (RNCs) to Sec translocons or Oxa1 superfamily insertases for co-translational insertion of membrane proteins. Upon insertion, transmembrane (TM) segments partition laterally according to their hydrophobicity and flanking charges, establishing membrane protein topology. Molecular chaperones and glycan-based quality-control systems—such as the calnexin/calreticulin (CNX/CRT) cycle—promote membrane protein folding and allow opportunities for refolding. Polypeptides that fail quality control are targeted for endoplasmic reticulum (ER)-associated degradation (ERAD), whereas correctly folded proteins are released for downstream trafficking and assembly. (B) Biogenesis of  $\beta$ -barrel membrane proteins (illustrated for outer membrane proteins in Gram-negative bacteria). Unfolded polypeptides of outer membrane proteins (OMPs) are exported through Sec translocons into the periplasm, where holdase chaperones capture and stabilize them in an assembly-competent state. The  $\beta$ -barrel assembly machinery (BAM) complex then couples folding with insertion into the outer membrane via a lateral-gate, yielding the native  $\beta$ -barrel architecture of OMPs.

residues (Dowhan et al., 2019; Knyazev et al., 2018; Driessen and Nouwen, 2008). Together, these mechanisms ensure that diverse membrane proteins insert with the correct topology while minimizing misfolding at early stages.

In the ER, Sec61 associates with accessory proteins such as the translocon-associated protein (TRAP) complex and the oligosaccharyltransferase (OST), enabling co-translational N-glycosylation (Fig. 2) (Sundaram et al., 2022; Russo, 2020). N-glycans act as both maturation timers and quality-control tags, directing monoglucosylated glycoproteins into the calnexin/calreticulin cycle (CNX/CRT cycle) (Guay et al., 2025; Caramelo and Parodi, 2008; Helenius and Aebi, 2004). The CNX/CRT cycle is an ER quality-control pathway in which the lectin chaperones CNX and CRT recognize monoglucosylated N-glycans and enable reglucosylation-dependent folding retries (Figs. 1A and 2). Luminal chaperones—including heat-shock protein 70 (HSP70; BiP in ER), heat-shock protein 40 (HSP40), and protein disulfide isomerase (PDI) family—complement this process by preventing aggregation and facilitating disulfide bond formation (Fig. 2) (Braakman and Bulleid, 2011; Anelli and Sitia, 2008). Together, these systems ensure that only properly folded glycoproteins exit the ER. Sec61 also collaborates with EMC and additional factors to coordinate the order of helix insertion, thereby preventing kinetic traps such as helix mispacking or premature oligomerization



**Fig. 2** Insertion and folding of multipass  $\alpha$ -helical membrane proteins at the endoplasmic reticulum. Once the ribosome-nascent chain complex (RNC) docks at the Sec61 translocon via the signal recognition particle (SRP) pathway and translation resumes, the nascent chain is threaded into the channel, where transmembrane (TM) segments form helices and partition laterally through the Sec61 lateral gate into the lipid bilayer. Insertion of TM helices is influenced by their hydrophobicity and flanking charges, lipid composition of the endoplasmic reticulum (ER), and the membrane potential. The ER membrane complex (EMC) assists helix insertion via the EMC3-EMC6 hydrophilic vestibule and cooperates with Sec61 to ensure the proper topology of multipass membrane proteins. In our schematic, one of the EMC modes illustrates the post-translational insertion of the C-terminal helix by EMC, completing the final membrane protein topology. With topology established by Sec61 and EMC, insertion is coupled to luminal modification and folding surveillance, where oligosaccharyltransferase (OST), acting in association with the translocon-associated protein (TRAP) complex, catalyzes N-glycosylation of exposed luminal loops, thereby stabilizing and refining TM orientation. These N-glycans can be monoglucosylated, recruiting calnexin (CNX) and chaperones (Hsp70, Hsp40, PDI) for lectin chaperone-mediated folding and quality control. Additionally, luminal chaperones—including heat-shock protein 70 (HSP70; BiP in ER), heat-shock protein 40 (HSP40), and protein disulfide isomerase (PDI) family—can prevent aggregation and promote disulfide bond formation.

(Hegde and Keenan, 2022; Chitwood and Hegde, 2019; Shurtleff et al., 2018). Thus, the ER translocon Sec61 is best understood not as a passive pore but as a dynamic assembly line that couples insertion, glycosylation, disulfide formation, and early folding quality control (Fig. 2).

In Gram-negative bacteria,  $\beta$ -barrel OMPs face a distinct biogenesis challenge due to their periplasmic transit. After Sec-dependent export into the periplasm, OMPs are captured and stabilized by holdase chaperones such as SurA and Skp, whereas DegP acts as a dual-function quality-control factor, transiently sequestering misfolded proteins and degrading those that fail to refold (Fig. 1B) (Devlin and Fleming, 2024; Goemans et al., 2014; Merdanovic et al., 2011; Sklar et al., 2007). Final insertion and folding are tightly coupled processes mediated by the BAM complex, composed of BamA and its associated lipoproteins (BamB–E) (Fig. 1B) (Noinaj et al., 2013, 2017; Hagan et al., 2011; Sklar et al., 2007). Structural studies support a lateral-gate model in which BamA transiently opens to locally perturb the membrane and template  $\beta$ -strand augmentation of nascent OMPs, enabling  $\beta$ -sheet closure and barrel formation (Noinaj et al., 2013, 2015, 2017; Bakelar et al., 2016; Gu et al., 2016). This process does not require ATP; instead, it is driven by the favorable free energy of  $\beta$ -sheet completion and bilayer partitioning, with periplasmic chaperones and BamA-mediated membrane remodeling lowering the kinetic barriers. Analogous machineries in eukaryotic organelles—including the sorting and assembly machinery (SAM) in mitochondria and outer envelope proteins (OEPs) in chloroplasts—highlight a conserved strategy for  $\beta$ -barrel protein biogenesis across compartments (Diederichs et al., 2021; Walther and Rapaport, 2009; Schleiff and Soll, 2005).

Because insertion and early folding are intrinsically error-prone, cells invest substantial resources in quality-control surveillance and triage mechanisms. In the ER, quality control is initiated co-translationally (Eisenack and Trentini, 2022; Ellgaard and Helenius, 2003): for example, the Sec63 J-domain recruits the heat-shock protein BiP, which then binds newly exposed luminal segments of the nascent chain as they emerge through Sec61 (Wentink et al., 2025; Otero et al., 2010). Subsequently, the lectin chaperones monitor glycoprotein folding through glucose trimming and UGGT-dependent reglucosylation, thereby providing retry signals

for incompletely folded substrates (Caramelo and Parodi, 2015). Stalled or collided ER-bound ribosomes activate ribosome-associated quality control (RQC) to eliminate defective nascent chains (Joazeiro, 2019; Brandman and Hegde, 2016). Misfolded or persistently unassembled membrane proteins are targeted to ER-associated degradation (ERAD), which is classically subdivided into ERAD-L (luminal domains), ERAD-M (TM domains), and ERAD-C (cytosolic domains) (Fig. 1A) (Sergejevs and Carvalho, 2025; Christianson et al., 2023; Christianson and Ye, 2014; Ruggiano et al., 2014). Substrates are captured by lectins and adaptors (e.g., OS-9 and EDEM for glycoproteins) and delivered to membrane-embedded E3 ubiquitin ligases (e.g., HRD1, gp78/AMFR, and MARCH6/TEB4) for ubiquitination. Retrotranslocation (dislocation) across the ER membrane converges on p97/VCP ATPase complexes, together with cofactors such as UFD1-NPL4, which extract ubiquitinated clients into the cytosol for proteasomal degradation. Structural and genetic data further support roles for HRD1 and Derlin family proteins in forming the retrotranslocation conduit (Guo et al., 2025; Rao et al., 2023; Schoebel et al., 2017; Greenblatt et al., 2011; Carvalho et al., 2010; Lilley and Ploegh, 2004). When ER burden exceeds capacity, the unfolded protein response (UPR) rebalances proteostatic flux by transiently reducing protein translation via the PERK signaling pathway, enhancing folding and ERAD capacities through ATF6 and IRE1 $\alpha$ -XBP1 signaling, and—if stress remains unresolved—initiating apoptosis (Hetz et al., 2020; Karagöz et al., 2019; Walter and Ron, 2011).


Comparable protein quality control logic operates in other compartments, adapted to their energetic and structural constraints. In bacteria, envelope quality control relies on stress-response regulons (Merdanovic et al., 2011; Silhavy et al., 2010; Ruiz et al., 2006): the  $\sigma^E$  and Cpx pathways upregulate periplasmic chaperones and proteases; SurA and Skp buffer OMP aggregation, while DegP (HtrA) clears terminally misfolded clients. At the inner membrane, the AAA<sup>+</sup> protease FtsH degrades misfolded or misassembled  $\alpha$ -helical membrane proteins (Yang et al., 2018; Ito and Akiyama, 2005). In mitochondria, the i-AAA protease YME1L and the m-AAA proteases AFG3L2/paraplegin monitor protein quality in the inner membrane, while OMA1 is activated by loss of membrane potential or related stresses to cleave OPA1 and remodel mitochondrial fusion-fission dynamics (Szczeponowska and Trifunovic, 2022; Quirós et al., 2015; Rugarli and Langer, 2012). When damage persists, mitophagy is engaged to eliminate defective organelles. In the eukaryotic ER, chronic stress triggers selective ER-phagy through dedicated receptors, providing a parallel route for clearing defective membrane proteins and remodeling stressed ER subdomains (Reggiori and Molinari, 2022; Wilkinson, 2020).

Overall, cells stabilize nascent chains, regulate the timing of insertion and assembly, and selectively remove nonproductive species, thereby restricting the accessible folding landscape to favor native outcomes (Okuyoneda et al., 2011; Walter and Ron, 2011; Hartl et al., 2011). Conversely, perturbations to translation kinetics, membrane lipid composition, cellular redox load, or electrochemical gradients can shift the folding balance, leading to long-lived off-pathway states. Thus, folding yield and fidelity are emergent properties of the entire biogenesis-quality control pipeline, rather than fixed traits of the polypeptide itself.

## Physicochemical principles of membrane protein folding

Protein folding in membranes is governed by the same fundamental physicochemical principles as water-soluble proteins, yet the lipid bilayer reshapes their relative contributions and constrains the accessible conformational space (Corin and Bowie, 2020). In other words, membrane protein folding cannot be decoded from sequence alone; rather, it arises from a contextual co-code between amino acid chemistry and the physicochemical properties of the lipid bilayer, which together determine topology, folding routes, and ultimately function (Levental and Lyman, 2023; Dowhan et al., 2019; Marsh, 2008; Bogdanov and Dowhan, 1999). Structurally, the lipid bilayer is only a few nanometers thick but highly anisotropic, providing a low-dielectric medium in which polarity decreases steeply from the aqueous interface, through the headgroup region, to the hydrocarbon core (Fig. 3) (Corin and Bowie, 2020; Nagle and Tristram-Nagle, 2000). The transfer of nonpolar side chains from water into the bilayer core yields a strong thermodynamic drive for hydrophobic burial (Moon and Fleming, 2011; Hessa et al., 2005; White and Wimley, 1999). However, desolvation of the peptide backbone is energetically unfavorable unless compensated by intramolecular hydrogen bonding (Bowie, 2011). Therefore, the formation of regular secondary structures such as  $\alpha$ -helices or  $\beta$ -sheets within the membrane is essential, as these motifs internally satisfy backbone hydrogen-bonding requirements and thereby offset the energetic cost of desolvation (Bowie, 2011; Moon and Fleming, 2011; White, 2005).

Lipid membranes are not passive solvents but active participants in membrane protein folding and function (Dowhan et al., 2019; Hong, 2015; Ding et al., 2015; Phillips et al., 2009). Bilayer properties—including thickness, headgroup charge, acyl-chain length and saturation, and sterol content—collectively define the lateral pressure profile and elastic moduli to which proteins must adapt (Andersen and Koeppe, 2007; Lee, 2004). Hydrophobic mismatch between a protein's effective hydrophobic length and the surrounding bilayer thickness imposes energetic penalties that can be relieved by helix tilt, local bilayer deformation, or lipid rearrangement (Fig. 3) (Andersen and Koeppe, 2007; Kandasamy and Larson, 2006; Hong and Tamm, 2004; Killian, 1998). See also chapter 6.12 on Membrane Protein-Lipid Match and Mismatch by O.G. Mouritsen in this volume. Cholesterol typically thickens and orders lipid bilayers, increasing their elastic moduli and promoting tighter molecular packing, although this effect diminishes in lipid bilayers enriched in polyunsaturated acyl chains (Doole et al., 2022; Pan et al., 2008, 2009; Rog et al., 2009; Lundbaek et al., 2003). In contrast, polyunsaturated lipids disorder and soften membranes, enhancing flexibility and lowering energetic barriers between conformational states (Baccouch et al., 2023). Beyond these generic effects, specific lipids can bind at non-annular sites to stabilize membrane proteins (Abramsson et al., 2025; Mukhaleva et al., 2024; Hedger et al., 2019; Guixà-González et al., 2017; Pan et al., 2008). Notable examples include cardiolipin bound to bacterial and mitochondrial transporters (Abramsson et al., 2025; Yi et al., 2022; Ruprecht et al., 2014; Pfeiffer et al., 2003), phosphatidylinositol-4,5-bisphosphate (PIP<sub>2</sub>) interacting



**Fig. 3** Physicochemical properties of lipid bilayers influencing membrane protein folding and stability. The lipid bilayer is an anisotropic medium with hydrophilic headgroup regions and a hydrophobic hydrocarbon core. At the water-bilayer interface, aromatic residues such as tryptophan (Trp) and tyrosine (Tyr) typically act as molecular anchors that stabilize membrane proteins. Through surface interaction with lipid headgroups while simultaneously contacting the hydrocarbon core, these aromatic residues help secure the placement of transmembrane (TM) helices. Lipid composition is heterogeneous across membranes and microdomains. Specific lipids such as phosphatidylinositol-4,5-bisphosphate (PIP<sub>2</sub>), cholesterol, and cardiolipin can stabilize particular conformations via site-specific binding, whereas the overall composition tunes membrane thickness, stiffness, and interfacial chemistry, thereby influencing membrane protein folding and stability. Hydrophobic matching refers to the condition in which the hydrophobic span of TM helices closely matches the hydrophobic thickness of the surrounding bilayer, minimizing energetic strain. Under hydrophobic mismatch (a disparity between helix span and bilayer hydrophobic thickness; indicated in red), helices may tilt and the membrane may remodel locally by thickening or thinning, thereby altering protein conformation and stability.

with basic interfacial patches of channels and transporters (Logothetis et al., 2007; Suh and Hille, 2005), and cholesterol molecules occupying defined cavities in GPCRs and ion channels (Hedger et al., 2019). Such specific lipid-protein interactions can tune equilibrium stabilities and modulate allosteric transitions (Fig. 3).

Aromatic residues such as tryptophan and tyrosine are enriched at the membrane interface, where their amphipathic character enables them to serve as aromatic anchors that stabilize TM helices at the water-lipid boundary (Fig. 3) (Hong et al., 2007; Killian and von Heijne, 2000; Yau et al., 1998). These residues interact simultaneously with the hydrocarbon core and interfacial headgroups, thereby minimizing the energetic penalty imposed by the steep polarity gradient across the membrane interface (Khemaissa et al., 2021; de Jesus and Allen, 2013; MacCallum et al., 2008). Likewise, basic residues such as lysine and arginine often snorkel toward the phospholipid headgroups, extending their charged side chains into the aqueous phase (MacCallum et al., 2008; Chamberlain et al., 2004; Strandberg and Killian, 2003). This behavior underlies the well-established positive-inside rule, which biases cytoplasmic loop orientation and exerts a strong influence on overall membrane protein topology (von Heijne, 2006; Vonheijne, 1989). These interfacial side-chain preferences act as sequence-encoded cues that link local chemical environments to the global processes of membrane insertion, folding, and topology determination (MacCallum et al., 2008; Hessa et al., 2005).

Interfacial water molecules and ions transiently sample the headgroup region, where local fluctuations can generate packing defects within the membrane (Alam et al., 2025; Karathanou and Bondar, 2018; Friedman, 2018; Pasenkiewicz-Gierula et al., 2016; Melcrová et al., 2016). Such defects can lower the energetic barriers for helix insertion and rearrangement, thereby facilitating conformational sampling and topological reorganization (Tripathy and Srivastava, 2023; Steinkuhler et al., 2022; Sikdar et al., 2021). At the same time, they can leave backbone desolvation incompletely compensated, creating nucleation sites for non-native interactions and potential misfolding (Fernández and Berry, 2003). Reactive oxygen species (ROS) and lipid peroxidation

products exacerbate these effects by disrupting lipid order and producing highly disordered interfacial regions (Balakrishnan and Kenworthy, 2024; Ferreira et al., 2016; Van der Paal et al., 2016; Jarerattanachai et al., 2013; Jurkiewicz et al., 2012; Wong-Ekkabut et al., 2007). These processes underscore the delicate balance at the membrane interface, where modest perturbations can steer folding outcomes toward either stable bilayer incorporation or, conversely, destabilization and aggregation.

Two principal architectures— $\alpha$ -helical bundles and  $\beta$ -barrels—dominate membrane protein structure, each following distinct folding principles (MacKenzie, 2006; Engelman et al., 2003; White and Wimley, 1999; Tomasek and Kahne, 2021; Horne et al., 2020; Danoff and Fleming, 2017; Kleinschmidt, 2015; Noinaj et al., 2015; Hagan et al., 2011). In  $\beta$ -barrel OMPs of bacterial and mitochondrial membranes, the alternating polar and nonpolar sequence pattern of  $\beta$ -strands imparts amphipathicity that drives insertion into the bilayer and promotes barrel closure through the formation of an extensive inter-strand hydrogen-bonding network (Dhar et al., 2021; Tamm et al., 2004). Their stability depends on structural parameters such as barrel radius, strand tilt, and loop architecture (Hermansen et al., 2022; Pali and Marsh, 2001; Murzin et al., 1994). Barrel closure typically makes  $\beta$ -barrels more tolerant to hydrophobic mismatch than  $\alpha$ -helical bundles, although they remain sensitive to interfacial electrostatics, curvature stress, and lipid composition (Machin et al., 2023; Horne et al., 2020; Srivastava et al., 2018; Danoff and Fleming, 2015; Hong and Tamm, 2004). In Gram-negative bacteria, for example, lipopolysaccharide (LPS) interacts electrostatically and through hydrogen bonding with basic residues in extracellular loops, thereby stabilizing  $\beta$ -barrel structures and promoting proper folding (Horne et al., 2020).


In  $\alpha$ -helical membrane proteins of the bacterial inner membrane and the eukaryotic ER, the lipid bilayer promotes helix formation because intramolecular hydrogen bonds within TM segments compensate for backbone desolvation in the low-dielectric core (Corin and Bowie, 2022; Hong, 2014). Subsequent steps—helix packing and oligomeric assembly—are governed largely by short-range van der Waals complementarity, often mediated by small-residue motifs such as GxxxG that enable tight helix-helix association (Teese and Langosch, 2015; Walters and DeGrado, 2006; Russ and Engelman, 2000; Javadpour et al., 1999). TM helices typically associate in pairs as helical hairpins, forming the fundamental unit of higher-order assemblies (Fig. 4a) (Kim et al., 2023; Corin and Bowie, 2022; Choi et al., 2019; Krainer et al., 2018; Engelman and Steitz, 1981). Helical hairpin formation in membranes occurs on a timescale of at least  $\sim 20$  ms which is about four orders of magnitude slower than the rapid folding of comparably sized soluble proteins (Kim et al., 2023). This kinetic slowdown arises from the high viscosity and limited lateral diffusivity of the lipid bilayer, which reduce the frequency of productive helix-helix encounters (Min, 2024; Kim et al., 2023). Interfacial salt bridges and hydrogen bonds function as molecular latches that stabilize established helical topologies, whereas reentrant loops and half-helices fine-tune ion or substrate permeation pathways (Pruitt et al., 2013; Romo et al., 2010; Jensen et al., 2003).

Folding of  $\alpha$ -helical membrane proteins, such as the *E. coli* rhomboid protease GlpG and the human  $\beta_2$ -adrenergic receptor, typically proceeds in an N-to-C direction, matching the vectorial emergence of the nascent chain into the lipid bilayer (Fig. 4a) (Choi et al., 2019; Min et al., 2015). As TM helices are synthesized and inserted via the Sec translocon, they are expected to fold locally—often as helical hairpins—soon after membrane insertion (Kim et al., 2025; Min, 2024). Because the lipid bilayer stabilizes secondary structure but resists large-scale rearrangements, early-formed helices can serve as nucleation sites that bias subsequent packing and template the folding of downstream helices (Paslawski et al., 2015). Once a folding nucleus forms, the bilayer helps lock in its structure, rendering early folding events kinetically persistent and difficult to reverse (Min, 2024; Kim et al., 2023; Choi et al., 2022; Min et al., 2018). This intrinsic folding asymmetry reflects built-in stability differences, topological constraints imposed by the translocon, and the vectorial nature of protein synthesis. This feature is also evident in many repeat-containing or multi-domain membrane proteins, including transporters (Choi et al., 2022; Min et al., 2018). For example, in the human glucose transporter GLUT3 and the *E. coli*  $\text{Cl}^-/\text{H}^+$  antiporter ClC-ec1, the N-terminal domain reliably folds first and serves as a structural template for the C-terminal half, with final interdomain assembly strongly influenced by lipid identity (Fig. 4b) (Choi et al., 2022; Min et al., 2018). Evolutionary analyses of GLUT family proteins suggest that sequence-encoded asymmetry and controlled metastability together define folding order, balancing foldability with functional optimization (Choi et al., 2022).

Many  $\alpha$ -helical membrane proteins achieve full functional stability only as dimers or higher-order oligomers (Ni and Hong, 2024; Hrmova, 2024; Corin and Bowie, 2022; Sleno and Hébert, 2018; Cymer and Schneider, 2012; Clarke and Gulbis, 2012). Molecular dynamics (MD) simulation studies suggest that their assembly can proceed through multiple TM domain association steps rather than a simple two-state on-off transition (Blazhynska et al., 2023; Lamprakis et al., 2021; Itaya et al., 2021; Domanski et al., 2017, 2020; Milligan et al., 2019; Dunton et al., 2014). A single-molecule tweezer platform has recently been adapted for studying membrane protein interactomes, allowing for the resolution of the post-diffusion dimerization dynamics of TMHC2, a designed TM helix homodimer without a defined physiological function (Sadongo et al., 2025). This work revealed three discrete dimerization domains that assemble sequentially during association, providing the first experimental evidence for a multi-step process for TM domain dimerization (Fig. 4c) (Sadongo et al., 2025). The overall dimer stability is governed by the TM-core domain, which exhibits extremely slow dissociation kinetics and thereby dominates the kinetic stability of the complex. These findings suggest that hidden, transient intermediates in TM helix association may be more common than previously appreciated and highlight a powerful single-molecule approach for probing TM protein-protein interactions in native-like membrane environments.

## Membrane protein misfolding and therapeutic approaches


Misfolding of membrane proteins contributes to pathology along two broad axes: loss of native function and the emergence of toxic gain of function (Fig. 5) (Marinko et al., 2019; Winklhofer et al., 2008). One major route in the loss-of-function mode is that



**Fig. 4** Folding and assembly mechanisms of  $\alpha$ -helical membrane proteins within lipid bilayers. Biophysical studies using single-molecule magnetic tweezers reveal key features of  $\alpha$ -helical membrane protein folding and assembly, including N-to-C folding, templated folding, and multi-step dimerization. (A) N-to-C folding. Following bilayer insertion of transmembrane (TM) helices, the N-terminal segment often folds first and can bias subsequent packing and folding toward the C-terminus, leading to the native state. This N-to-C folding direction matches the direction of protein translation, supporting co-translational folding. During each folding step, a TM helix harpin typically serves as a stable structural unit, representing a folding intermediate. Example proteins include the *E. coli* rhomboid protease GlpG and the human  $\beta_2$ -adrenergic receptor. (B) Templated folding. For multi-domain membrane proteins such as those in the major facilitator superfamily (MFS) that follow the N-to-C folding pathway, the N-terminal domain (N-domain) similarly folds first, followed by folding of the C-terminal domain (C-domain). Once both domains are folded, interdomain assembly brings them together into the native structure. The N-domain can sometimes be more stable than the C-domain, acting as a structural template and thereby facilitating the interdomain assembly. The dashed arrows indicate that multiple intermediates may exist during the folding of each domain. Example proteins include the human glucose transporter GLUT3 and the *E. coli*  $\text{Cl}^-/\text{H}^+$  antiporter CIC-ec1. (C) Multi-step dimerization. Separated monomers first encounter one another by lateral diffusion within the lipid bilayer. Once initial binding occurs, post-diffusion dimerization proceeds through a series of discrete, short-lived intermediates that reflect the stepwise engagement of distinct TM association domains. The fully assembled dimer state is ultimately established through this multi-step dimerization process. Example proteins include the designed TM helix homodimer TMHC2.

unstable variants are retained in the ER and targeted for ERAD, thereby reducing surface expression, even though properly folded states would have been functional (Marinko et al., 2019; Denny et al., 2013; Guerriero and Brodsky, 2012; Vembar and Brodsky, 2008). The cystic fibrosis transmembrane conductance regulator (CFTR), an ATP-gated chloride channel of the ATP-binding cassette (ABC) transporter family, provides a prime example: the  $\Delta\text{F508}$  mutation destabilizes nucleotide-binding domain interactions, leading to excessive ER retention and degradation while impairing trafficking and chloride transport—molecular hallmarks of cystic fibrosis (Lukacs and Verkman, 2012). Mutations in members of the CIC chloride channel family can disrupt helix-packing interfaces, leading to misassembly or gating defects that cause myotonia congenita (Jentsch and Pusch, 2018). Variants in KCNQ voltage-gated potassium channels that destabilize the voltage-sensor domain or impair gating can give rise to long-QT syndromes and epilepsies (Huang et al., 2018; Wu et al., 2016; Orhan et al., 2014). Destabilization of ABC lipid transporters (e.g., ABCA1, ABCG1, and ABCG5/8) and of the NPC1/NPC2 cholesterol-handling system underlies Tangier disease (ABCA1) and





**Fig. 5** Consequences of proteostasis collapse in membrane proteins. Under balanced proteostasis, folding, trafficking, and degradation are tightly coordinated to maintain cellular homeostasis. When this network collapses, however, misfolded or misassembled membrane proteins can accumulate. Moreover, in the collapsed state, trafficking between the endoplasmic reticulum and Golgi apparatus (ER-Golgi trafficking) can fail, reducing delivery to the plasma membrane and thereby decreasing surface expression. This contributes to a loss-of-function phenotype. More broadly, three major pathological outcomes of proteostasis collapse in membrane proteins can arise: (i) loss of native function, including reduced surface expression or defects in channel gating; (ii) toxic gain of function, including signaling dysregulation by aberrant adaptor engagement or aggregation and fibril formation triggered by aberrant enzymatic processing; and (iii) membrane-coupled misfolding and toxicity, including membrane-permeabilizing pore formation or membrane-associated aggregation.

Niemann-Pick type C disease (NPC1/NPC2), respectively (Vanier, 2010; Oram and Vaughan, 2006; Baldan et al., 2006; Scott and Ioannou, 2004).

Misfolded or misassembled membrane proteins can acquire aberrant activities that compromise cellular integrity (Fig. 5) (Marinko et al., 2019). For example, the  $\gamma$ -secretase complex, with presenilin as its catalytic core, requires assisted assembly in the bilayer, with dedicated factors and precise stoichiometry guiding the formation of a functional enzyme (Almén et al., 2009; Sato et al., 2007; Edbauer et al., 2003). However, pathogenic variants destabilize the complex and shift amyloid precursor protein (APP) processing toward amyloid- $\beta$ 42 ( $A\beta$ 42), thereby increasing the  $A\beta$ 42/40 ratio characteristic of familial Alzheimer's disease (Szaruga et al., 2017; Chávez-Gutiérrez et al., 2012; Shen and Kelleher, 2007). Misassembled subunits can also exert dominant-negative effects by trapping wild-type partners in nonfunctional complexes, as observed in dimeric ion channels and ABC transporters (Rinne et al., 2015, 2024; Jentsch and Pusch, 2018; Graf et al., 2004; Kubisch et al., 1998). Likewise, GPCR variants can aberrantly engage cytosolic scaffold or adaptor proteins in a ligand-independent manner, promoting receptor desensitization and internalization and thereby disrupting downstream signaling (Kocan et al., 2009).

In many cases, loss of native function and toxic gain of function are not mutually exclusive but operate concurrently within the same system (Balendra and Isaacs, 2018; Winklhofer et al., 2008). In the retina, for example, P23H rhodopsin mutants misfold in the ER and are largely eliminated by ERAD, reducing surface expression and impairing phototransduction (Griciuc et al., 2010; Illing et al., 2002). Yet, residual species that evade quality control can accumulate at the membrane, where they misassemble and exert toxic gain of function in retinitis pigmentosa (Sakami et al., 2014; Haeri and Knox, 2012). Within mitochondria, oxidative stress destabilizes the proteome at multiple levels: cardiolipin peroxidation compromises respiratory-chain supercomplexes and reduces oxidative phosphorylation capacity, while misfolding of transporters and assembly factors activates mitophagy and drives


bioenergetic collapse (Schlame and Greenberg, 2017; Paradies et al., 2014a). These primary losses of function are further amplified by secondary toxic outputs, notably ROS and lipid peroxidation (Paradies et al., 2014a, 2014b). While ROS broadly oxidize proteins and lipids, lipid peroxidation specifically generates hydroperoxides and reactive carbonyl species (RCS; e.g., 4-HNE and 4-HHE), which soften and thin membranes while covalently modifying residues such as Lys, His, Cys, Met, and Trp (Gaschler and Stockwell, 2017; Runas and Malmstadt, 2015; Wong-Ekkabut et al., 2007; Yamada et al., 2004; Doorn and Petersen, 2002). Such membrane modulation and residue modifications can destabilize helix-helix packing interactions, thereby promoting misfolded or misassembled states (Wiczew et al., 2021; Van der Paal et al., 2016; Liu et al., 2008).

Interactions with lipid membranes constitute another critical dimension of misfolding pathology (Fig. 5) (Mirdha, 2024; Hong, 2015). Although A $\beta$  and  $\alpha$ -synuclein are not canonical TM proteins, their oligomers associate with and remodel membranes, generating Ca<sup>2+</sup>-permeable defects that exemplify toxic gain of function at the bilayer and contribute to the pathogenesis of Alzheimer's and Parkinson's diseases (Fusco et al., 2017; Demuro et al., 2005, 2011; Lashuel et al., 2002). Likewise, the prion protein (PrP), tethered to the outer leaflet of the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor, undergoes conformational conversion from an  $\alpha$ -helix- to a  $\beta$ -sheet-rich state within cholesterol- and sphingolipid-rich microdomains, where altered membrane composition can promote PrP aggregation and drive transmissible prion diseases (Conceicao et al., 2023; Puig et al., 2014; Baron et al., 2002; Taylor and Hooper, 2006). Beyond these protein-specific interactions, the physical properties of the bilayer itself constitute additional determinants of misfolding (Vendruscolo, 2022). The effective hydrophobic length of TM segments must match membrane thickness: deviations can bias helices toward nonnative packing or oligomeric stoichiometries (Bernhardt et al., 2025; Chadda et al., 2021; Marinko et al., 2019; Andersen and Koeppe, 2007; Jensen and Mouritsen, 2004). Cells normally tune bilayer thickness (e.g., via cholesterol and sphingolipid enrichment) to support their membrane proteome, but an imbalance imposes elastic penalties that misdirect folding pathways (Holthuis and Menon, 2014; van Meer et al., 2008). Accumulation of ceramides or lysolipids can introduce packing defects that promote misfolding and aberrant protein-protein associations (Lima et al., 2025; Lai et al., 2023; Kurzawa-Akanbi et al., 2021; Sheikh and Nagai, 2011).

Pharmaceuticals have conventionally targeted membrane protein function via agonists, antagonists, and channel blockers (Zhang et al., 2024; Santos et al., 2017; Bagal et al., 2013). A complementary strategy is to reshape the folding landscape to increase the fraction of molecules that reach and remain in the native basin (Marinko et al., 2019; Beerepoot et al., 2017; Wang et al., 2014; Leidenheimer and Ryder, 2014; Tao and Conn, 2014; Mendre and Mouillac, 2010; White et al., 2009; Bernier et al., 2004; Morello et al., 2000a). This can be pursued through several key levers, the first involving small-molecule stabilizers that thermodynamically favor native or near-native conformations (Fig. 6) (Van Goor et al., 2011; Bernier et al., 2004; Morello et al., 2000a; Sato et al., 1996). Orthosteric ligands mimic endogenous ligands—or occupy the same binding site—and can stabilize the bound conformation, thereby rescuing trafficking of otherwise unstable variants (Van Goor et al., 2011; Mendre and Mouillac, 2010; Bernier et al., 2004; Morello et al., 2000a; Sato et al., 1996). Classic examples include retinal analogs such as 9-cis-retinal, which stabilize misfolded opsins and restore trafficking in models of retinitis pigmentosa (Chen et al., 2014; Mendes and Cheetham, 2008; Noorwez et al., 2004; Saliba et al., 2002); vasopressin V2 receptor (V2R) antagonists such as SR121463 and VPA-985, which recover surface expression of V2R mutants associated with nephrogenic diabetes insipidus (Robben et al., 2007; Wüller et al., 2004; Morello et al., 2000b); and small-molecule orthosteric ligands such as propranolol for the  $\beta_2$ -adrenergic receptor and IN3 for the gonadotropin-releasing hormone receptor (GnRHR), both of which enhance folding and trafficking efficiency in misfolded variants (Parmar et al., 2017; Conn and Janovick, 2009; Janovick et al., 2002, 2003).

In contrast, allosteric stabilizers engage structurally privileged sites—including interhelical grooves, lipid-facing pockets, and seam interfaces—providing stabilization without requiring similarity to endogenous ligands (Fig. 6) (Fiedorczuk and Chen, 2022; Kruse et al., 2013; Janovick et al., 2009). In the calcium-sensing receptor (CaSR), the positive allosteric modulator cinacalcet—clinically used for hyperparathyroidism and chronic renal disease—rescues misfolded receptor mutants associated with familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism by promoting folding and surface trafficking (Huang et al., 2011; Reh et al., 2011). Likewise, positive allosteric modulators of the  $\gamma$ -aminobutyric acid type B (GABAB) receptor, such as CGP7930, facilitate maturation and plasma-membrane trafficking of misfolded subunits, while simultaneously enhancing receptor signaling (Adams and Lawrence, 2007). Lumacaftor (VX-809), typically classified as a CFTR corrector, also functions as an allosteric stabilizer of  $\Delta$ F508-CFTR, improving folding and ER export, albeit without fully correcting the gating defect (Van Goor et al., 2011). Interestingly, certain pharmacological chaperones—regardless of whether they bind at orthosteric or allosteric sites—can act dually as negative modulators of receptor activity and positive modulators of protein biogenesis. For example, YC-001 suppresses basal rhodopsin signaling while promoting its proper folding and forward trafficking to the plasma membrane (Chen et al., 2018).

Proteostasis modulators alter the capacity and stringency of cellular protein quality control networks (Fig. 6) (Yang et al., 2024; Balch et al., 2008). By tuning the UPR, ER chaperone activity, ERAD flux, or autophagy, cells can influence how marginal folding intermediates are triaged between rescue and degradation, thereby increasing the overall folding yield and improving surface delivery (Wiseman et al., 2022; Wang and Kaufman, 2016; Anelli and Sitia, 2008). For example, celastrol, a natural triterpene that induces the heat-shock response, has been shown to enhance ER export of  $\Delta$ F508-CFTR by upregulating molecular chaperones and thereby augmenting the folding capacity of the ER (Mu et al., 2008). Conceptually, this lever also includes regulating translocon and insertase assistance during co-translational insertion, which is particularly important for multipass GPCRs and ion channels whose folding efficiency depends on ribosome-Sec61 dynamics (Smalinskaitė and Hegde, 2023). Small molecules such as eeyares-tatin I, CAM741, and CADA illustrate how pharmacological perturbation of Sec61 gating can alter the insertion and maturation of



**Fig. 6** Therapeutic intervention in membrane protein proteostasis. During protein synthesis, nascent polypeptides emerge in a fully or partially unfolded state and ultimately reach their native conformation through co- and post-translational folding. Therapeutic strategies can intervene at multiple points along this pathway. Small-molecule modulators—including orthosteric ligands and allosteric ligands—can remodel the folding energy landscape to favor the native conformation, thereby enhancing surface expression and functional activity. Proteostasis modulators can act on unfolded protein response (UPR) signaling, augment endoplasmic reticulum (ER) chaperone networks, and enhance ER-associated degradation (ERAD) or autophagy, thereby increasing folding efficiency and promoting forward trafficking. Targeted degradation strategies selectively eliminate pathogenic protein species by recruiting endogenous degradation machinery—proteasome engagement via proteolysis-targeting chimeras (PROTACs) or lysosomal uptake via lysosome-targeting chimeras (LYTACs)—while minimizing effects on native functional protein populations.

membrane proteins, underscoring early biogenesis steps as a potential therapeutic target (Xin et al., 2025; Hassdenteufel et al., 2018; Linxweiler et al., 2017).

Targeted degradation emerges as a critical therapeutic approach, prioritizing elimination over folding rescue (Fig. 6) (Zhao et al., 2022; Alabi and Crews, 2021). Platforms such as proteasome-targeting chimeras (PROTACs), lysosome-targeting chimeras (LYTACs), and related targeted degraders are being extended to membrane proteins, including GPCRs and RTKs (Keen et al., 2024; Xie et al., 2023; Bekes et al., 2022; Huber et al., 2022; Burslem et al., 2018a, 2018b; Powell et al., 2018; Santos et al., 2017; Sakamoto et al., 2001). ARV-110 and ARV-471 represent first-in-class PROTACs that degrade nuclear hormone receptors and have advanced to clinical trials, establishing proof of the modality (Ma and Zhou, 2025; Arnold, 2024; Mullard, 2019, 2021). In parallel, preclinical PROTACs directed against membrane proteins such as epidermal growth factor receptor (EGFR) and c-Met receptor demonstrate feasibility for therapeutic downregulation of RTKs (Ruffilli et al., 2025; Burslem et al., 2018a). Likewise, EGFR-directed LYTACs, including antibody-glycoprotein conjugates such as cetuximab-based constructs, have been shown to induce lysosomal degradation of EGFR and effectively deplete pathogenic receptor pools (Ahn et al., 2021, 2023; Banik et al., 2020). The therapeutic goal in these cases is not to rescue folding but to selectively eliminate pathogenic protein populations while sparing—and in some cases indirectly enhancing—the functional wild-type pool (Alabi et al., 2021). Future therapeutic strategies will likely integrate folding rescue with targeted degradation to finely tune membrane protein homeostasis.

## Outlook

This chapter has outlined how membrane proteins fold within the complex environment of the lipid bilayer, covering cellular folding pathways, their physicochemical principles, the pathological consequences of misfolding, and emerging therapeutic interventions. Overall, these perspectives emphasize that the fidelity of membrane protein folding is not determined by sequence alone but arises from dynamic interactions among proteins, lipids, and quality-control systems. Future advances are likely to come from the integration of high-resolution single-molecule biophysics, multiscale computational approaches, and cell-based folding assays,

which together can capture co-translational and lipid-dependent influences on membrane protein folding in real time. A deeper understanding of these processes will, in turn, help elucidate the mechanisms of misfolding-related diseases and guide the development of therapeutic strategies.

## Acknowledgments

This work was supported by the National Research Foundation of Korea (RS-2025-00513015 to D.M.).

## References

- Abramsson, M.L., Corey, R.A., Skerle, J.L., Persson, L.J., Anden, O., Oluwole, A.O., Howard, R.J., Lindahl, E., Robinson, C.V., Strisovsky, K., Marklund, E.G., Drew, D., Stansfeld, P.J., Landreh, M., 2025. Engineering cardiolipin binding to an artificial membrane protein reveals determinants for lipid-mediated stabilization. *eLife* 14.
- Adams, C.L., Lawrence, A.J., 2007. CGP7930: a positive allosteric modulator of the GABAB receptor. *CNS Drug Rev.* 13, 308–316.
- Ahn, G., Banik, S.M., Miller, C.L., Riley, N.M., Cochran, J.R., Bertozzi, C.R., 2021. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation. *Nat. Chem. Biol.* 17, 937–946.
- Ahn, G., Riley, N.M., Kamber, R.A., Wisnovsky, S., Moncayo Von Hase, S., Bassik, M.C., Banik, S.M., Bertozzi, C.R., 2023. Elucidating the cellular determinants of targeted membrane protein degradation by lysosome-targeting chimeras. *Science* 382, eadf6249.
- Alabi, S.B., Crews, C.M., 2021. Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs. *J. Biol. Chem.* 296, 100647.
- Alabi, S., Jaime-Figueroa, S., Yao, Z., Gao, Y., Hines, J., Samarasinghe, K.T.G., Vogt, L., Rosen, N., Crews, C.M., 2021. Mutant-selective degradation by BRAF-targeting PROTACs. *Nat. Commun.* 12, 920.
- Alam, P., Kumar, P., Sahu, H., Sardana, D., Kundu, P., Chand, A.K., Sen, S., 2025. Effect of divalent cations on polarity and hydration at the lipid/water interface probed by 4-Aminophthalimide-Based dyes. *J. Phys. Chem. B* 129, 930–941.
- Almén, M.S., Nordström, K.J.V., Fredriksson, R., Schiöth, H.B., 2009. Mapping the human membrane proteome: a majority of the human membrane proteins can be classified according to function and evolutionary origin. *BMC Biol.* 7.
- Andersen, O.S., Koeppe, R.E., 2007. Bilayer thickness and membrane protein function: an energetic perspective. *Annu. Rev. Biophys. Biomol. Struct.* 36, 107–130.
- Anelli, T., Sitia, R., 2008. Protein quality control in the early secretory pathway. *EMBO J.* 27, 315–327.
- Arnold, C., 2024. PROTAC protein degraders to drug the undruggable enter phase 3 trials. *Nat. Med.* 30, 3030–3031.
- Arya, S.S., Morsy, N.K., Islayem, D.K., Alkhatib, S.A., Pitsalidis, C., Pappa, A.M., 2023. Bacterial membrane mimetics: from biosensing to disease prevention and treatment. *Biosensors (Basel)* 13.
- Baccouch, R., Shi, Y., Vernay, E., Mathelie-Guinlet, M., Taib-Maamar, N., Vilette, S., Feuillie, C., Rascol, E., Nuss, P., Lecomte, S., Molinari, M., Staneva, G., Alves, I.D., 2023. The impact of lipid polyunsaturation on the physical and mechanical properties of lipid membranes. *Biochim. Biophys. Acta Biomembr.* 1865, 184084.
- Bagal, S., Brown, A.D., Cox, P.J., Omoto, K., Owen, R.M., Pryde, D.C., Sidders, B., Skerratt, S.E., Stevens, E.B., Storer, R.I., Swain, N.A., 2013. Ion channels as therapeutic targets: a drug discovery perspective. *J. Med. Chem.* 56, 593–624.
- Bakelar, J., Buchanan, S.K., Noinaj, N., 2016. The structure of the  $\beta$ -barrel assembly machinery complex. *Science* 351, 180–186.
- Balakrishnan, M., Kenworthy, A.K., 2024. Lipid peroxidation drives liquid-liquid phase separation and disrupts raft protein partitioning in biological membranes. *J. Am. Chem. Soc.* 146, 1374–1387.
- Balch, W.E., Morimoto, R.I., Dillin, A., Kelly, J.W., 2008. Adapting proteostasis for disease intervention. *Science* 319, 916–919.
- Baldan, A., Tarr, P., Lee, R., Edwards, P.A., 2006. ATP-binding cassette transporter G1 and lipid homeostasis. *Curr. Opin. Lipidol.* 17, 227–232.
- Balendra, R., Isaacs, A.M., 2018. C9orf72-mediated ALS and FTD: multiple pathways to disease. *Nat. Rev. Neurol.* 14, 544–558.
- Banik, S.M., Pedram, K., Wisnovsky, S., Ahn, G., Riley, N.M., Bertozzi, C.R., 2020. Lysosome-targeting chimeras for degradation of extracellular proteins. *Nature* 584, 291–297.
- Baron, G.S., Wehrly, K., Dorward, D.W., Chesebro, B., Caughey, B., 2002. Conversion of raft associated prion protein to the protease-resistant state requires insertion of PrP-res (PrP) into contiguous membranes. *EMBO J.* 21, 1031–1040.
- Beerepoot, P., Nazari, R., Salahpour, A., 2017. Pharmacological chaperone approaches for rescuing GPCR mutants: current state, challenges, and screening strategies. *Pharmacol. Res.* 117, 242–251.
- Bekes, M., Langley, D.R., Crews, C.M., 2022. PROTAC targeted protein degraders: the past is prologue. *Nat. Rev. Drug Discov.* 21, 181–200.
- Bernhardt, N., Öztürk, T.N., Zhang, S., Schwartz, N., Chadda, R., Gil-Ley, A., Robertson, J.L., Faraldo-Gomez, J.D., 2025. Molecular basis for the regulation of membrane proteins through preferential lipid solvation. *Nat. Chem. Biol.*
- Bernier, V., Lagace, M., Bichet, D.G., Bouvier, M., 2004. Pharmacological chaperones: potential treatment for conformational diseases. *Trends Endocrinol. Metabol.* 15, 222–228.
- Blazhynska, M., Gumbart, J.C., Chen, H., Tajkhorshid, E., Roux, B., Chipot, C., 2023. A rigorous framework for calculating protein-protein binding affinities in membranes. *J. Chem. Theor. Comput.* 19, 9077–9092.
- Bogdanov, M., Dowhan, W., 1999. Lipid-assisted protein folding. *J. Biol. Chem.* 274, 36827–36830.
- Bowie, J.U., 2011. Membrane protein folding: how important are hydrogen bonds? *Curr. Opin. Struct. Biol.* 21, 42–49.
- Braakman, I., Bulleid, N.J., 2011. Protein folding and modification in the mammalian endoplasmic reticulum. *Annu. Rev. Biochem.* 80 (80), 71–99.
- Brandman, O., Hegde, R.S., 2016. Ribosome-associated protein quality control. *Nat. Struct. Mol. Biol.* 23, 7–15.
- Burslem, G.M., Smith, B.E., Lai, A.C., Jaime-Figueroa, S., McQuaid, D.C., Bondeson, D.P., Toure, M., Dong, H., Qian, Y., Wang, J., Crew, A.P., Hines, J., Crews, C.M., 2018a. The advantages of targeted protein degradation over inhibition: an RTK case study. *Cell Chem. Biol.* 25, 67–77 e3.
- Burslem, G.M., Song, J., Chen, X., Hines, J., Crews, C.M., 2018b. Enhancing antiproliferative activity and selectivity of a FLT-3 inhibitor by proteolysis targeting chimera conversion. *J. Am. Chem. Soc.* 140, 16428–16432.
- Caliseki, M., Schaffitzel, C., Kabasakal, B.V., 2025. The versatile role of YidC in membrane protein biosynthesis and quality control. *Biochim. Biophys. Acta Mol. Cell Res.* 1872.
- Cantor, R.S., 1999. Lipid composition and the lateral pressure profile in bilayers. *Biophys. J.* 76, 2625–2639.
- Caramelo, J.J., Parodi, A.J., 2008. Getting in and out from calnexin/calreticulin cycles. *J. Biol. Chem.* 283, 10221–10225.
- Caramelo, J.J., Parodi, A.J., 2015. A sweet code for glycoprotein folding. *FEBS Lett.* 589, 3379–3387.
- Carvalho, P., Stanley, A.M., Rapoport, P.A., 2010. Retrotranslocation of a misfolded luminal ER protein by the ubiquitin-ligase Hrd1p. *Cell* 143, 579–591.
- Chadda, R., Bernhardt, N., Kelley, E.G., Teixeira, S.C.M., Griffith, K., Gil-Ley, A., Öztürk, T.N., Hughes, L.E., Forsythe, A., Krishnamani, V., Faraldo-Gomez, J.D., Robertson, J.L., 2021. Membrane transporter dimerization driven by differential lipid solvation energetics of dissociated and associated states. *eLife* 10.
- Chamberlain, A.K., Lee, Y., Kim, S., Bowie, J.U., 2004. Snorkeling preferences foster an amino acid composition bias in transmembrane helices. *J. Mol. Biol.* 339, 471–479.

- Chávez-Gutiérrez, L., Bammens, L., Benilova, I., Vandersteen, A., Benurwar, M., Borgers, M., Lismont, S., Zhou, L.J., Van Cleynebreugel, S., Esselmann, H., Wiltfang, J., Serneels, L., Karran, E., Gijzen, H., Schymkowitz, J., Rousseau, F., Broersen, K., De Strooper, B., 2012. The mechanism of  $\gamma$ -Secretase dysfunction in familial Alzheimer disease. *EMBO J.* 31, 2261–2274.
- Chen, Y., Jastrzebska, B., Cao, P., Zhang, J., Wang, B., Sun, W., Yuan, Y., Feng, Z., Palczewski, K., 2014. Inherent instability of the retinitis pigmentosa P23H mutant opsin. *J. Biol. Chem.* 289, 9288–9303.
- Chen, Y., Capponi, S., Zhu, L., Gellenbeck, P., Freitas, J.A., White, S.H., Dalbey, R.E., 2017. YidC insertase of *Escherichia coli*: water accessibility and membrane shaping. *Structure* 25, 1403–1414 e3.
- Chen, Y., Chen, Y., Jastrzebska, B., Golczak, M., Gulati, S., Tang, H., Seibel, W., Li, X., Jin, H., Han, Y., Gao, S., Zhang, J., Liu, X., Heidari-Torkabadi, H., Stewart, P.L., Harte, W.E., Tochtrop, G.P., Palczewski, K., 2018. A novel small molecule chaperone of rod opsin and its potential therapy for retinal degeneration. *Nat. Commun.* 9, 1976.
- Chitwood, P.J., Hegde, R.S., 2019. The role of EMC during membrane protein biogenesis. *Trends Cell Biol.* 29, 371–384.
- Chitwood, P.J., Juszkievicz, S., Guna, A., Shao, S.C., Hegde, R.S., 2018. EMC is required to initiate accurate membrane protein topogenesis. *Cell* 175, 1507.
- Choi, H.K., Min, D., Kang, H., Shon, M.J., Rah, S.H., Kim, H.C., Jeong, H., Choi, H.J., Bowie, J.U., Yoon, T.Y., 2019. Watching helical membrane proteins fold reveals a common N-to-C-terminal folding pathway. *Science* 366, 1150–1156.
- Choi, H.K., Kang, H., Lee, C., Kim, H.G., Phillips, B.P., Park, S., Tumescheit, C., Kim, S.A., Lee, H., Roh, S.H., Hong, H., Steinegger, M., Im, W., Miller, E.A., Choi, H.J., Yoon, T.Y., 2022. Evolutionary balance between foldability and functionality of a glucose transporter. *Nat. Chem. Biol.* 18, 713–723.
- Christianson, J.C., Ye, Y.H., 2014. Cleaning up in the endoplasmic reticulum: ubiquitin in charge. *Nat. Struct. Mol. Biol.* 21, 325–335.
- Christianson, J.C., Jarosch, E., Sommer, T., 2023. Mechanisms of substrate processing during ER-associated protein degradation. *Nat. Rev. Mol. Cell Biol.* 24, 777–796.
- Clarke, O.B., Gulbis, J.M., 2012. Oligomerization at the membrane potassium channel structure and function. *Protein Dimerization and Oligomerization in Biology* 747, 122–136.
- Conceicao, C.A., De Lemos, G.A., Barros, C.A., Vieira, T.C.R.G., 2023. What is the role of lipids in prion conversion and disease? *Front. Mol. Neurosci.* 15.
- Conn, P.M., Janovick, J.A., 2009. Drug development and the cellular quality control system. *Trends Pharmacol. Sci.* 30, 228–233.
- Corin, K., Bowie, J.U., 2020. How bilayer properties influence membrane protein folding. *Protein Sci.* 29, 2348–2362.
- Corin, K., Bowie, J.U., 2022. How physical forces drive the process of helical membrane protein folding. *EMBO Rep.* 23, e53025.
- Cymer, F., Schneider, D., 2012. Oligomerization of polytopic  $\alpha$ -helical membrane proteins: causes and consequences. *Biol. Chem.* 393, 1215–1230.
- Cymer, F., Von Heijne, G., White, S.H., 2015. Mechanisms of integral membrane protein insertion and folding. *J. Mol. Biol.* 427, 999–1022.
- Dalbey, R.E., Kaushik, S., Kuhn, A., 2023. YidC as a potential antibiotic target. *Biochim. Biophys. Acta Mol. Cell Res.* 1870.
- Danoff, E.J., Fleming, K.G., 2015. Membrane defects accelerate outer membrane beta-barrel protein folding. *Biochemistry* 54, 97–99.
- Danoff, E.J., Fleming, K.G., 2017. Novel kinetic intermediates populated along the folding pathway of the transmembrane  $\beta$ -Barrel OmpA. *Biochemistry* 56, 47–60.
- De Jesus, A.J., Allen, T.W., 2013. The role of tryptophan side chains in membrane protein anchoring and hydrophobic mismatch. *Biochim. Biophys. Acta Biomembr.* 1828, 864–876.
- Demuro, A., Mina, E., Kaye, R., Milton, S.C., Parker, I., Glabe, C.G., 2005. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. *J. Biol. Chem.* 280, 17294–17300.
- Demuro, A., Smith, M., Parker, I., 2011. Single-channel Ca imaging implicates A $\beta$  1–42 amyloid pores in Alzheimer's disease pathology. *JCB (J. Cell Biol.)* 195, 515–524.
- Denny, R.A., Gavrin, L.K., Saiah, E., 2013. Recent developments in targeting protein misfolding diseases. *Bioorg. Med. Chem. Lett* 23, 1935–1944.
- Devlin, T., Fleming, K.G., 2024. A team of chaperones play to win in the bacterial periplasm. *Trends Biochem. Sci.* 49, 667–680.
- Dhar, R., Feehan, R., Slusky, J.S.G., 2021. Membrane barrels are taller, fatter, inside-out soluble barrels. *J. Phys. Chem. B* 125, 3622–3628.
- Diederichs, K.A., Buchanan, S.K., Botos, I., 2021. Building better barrels -  $\beta$ -barrel biogenesis and insertion in bacteria and mitochondria. *J. Mol. Biol.* 433.
- Ding, W., Palaiokostas, M., Wang, W., Orsi, M., 2015. Effects of lipid composition on bilayer membranes quantified by all-atom molecular dynamics. *J. Phys. Chem. B* 119, 15263–15274.
- Dobson, L., Szekeeres, L.I., Gerdan, C., Lango, T., Zeke, A., Tusnady, G.E., 2023. TmAlphaFold database: membrane localization and evaluation of AlphaFold2 predicted alpha-helical transmembrane protein structures. *Nucleic Acids Res.* 51, D517–D522.
- Domanski, J., Hedger, G., Best, R.B., Stansfeld, P.J., Sansom, M.S.P., 2017. Convergence and sampling in determining free energy landscapes for membrane protein association. *J. Phys. Chem. B* 121, 3364–3375.
- Domanski, J., Sansom, M.S.P., Stansfeld, P.J., Best, R.B., 2020. Atomistic mechanism of transmembrane helix association. *PLoS Comput. Biol.* 16, e1007919.
- Doole, F.T., Kumarage, T., Ashkar, R., Brown, M.F., 2022. Cholesterol stiffening of lipid membranes. *J. Membr. Biol.* 255, 385–405.
- Doorn, J.A., Petersen, D.R., 2002. Covalent modification of amino acid nucleophiles by the lipid peroxidation products 4-hydroxy-2-nonenal and 4-oxo-2-nonenal. *Chem. Res. Toxicol.* 15, 1445–1450.
- Dowhan, W., Vitrac, H., Bogdanov, M., 2019. Lipid-assisted membrane protein folding and topogenesis. *Protein J.* 38, 274–288.
- Driessen, A.J.M., Nouwen, N., 2008. Protein translocation across the bacterial cytoplasmic membrane. *Annu. Rev. Biochem.* 77, 643–667.
- Duart, G., Graña-Montes, R., Pastor-Cantizano, N., Mingarro, I., 2024. Experimental and computational approaches for membrane protein insertion and topology determination. *Methods* 226, 102–119.
- Dunton, T.A., Goose, J.E., Gavaghan, D.J., Sansom, M.S., Osborne, J.M., 2014. The free energy landscape of dimerization of a membrane protein, NanC. *PLoS Comput. Biol.* 10, e1003417.
- Edbauer, D., Winkler, E., Regula, J.T., Pesold, B., Steiner, H., Haass, C., 2003. Reconstitution of  $\gamma$ -secretase activity. *Nat. Cell Biol.* 5, 486–488.
- Eisenack, T.J., Trentini, D.B., 2022. Ending a bad start: triggers and mechanisms of co-translational protein degradation. *Front. Mol. Biosci.* 9, 1089825.
- Elgaard, L., Helenius, A., 2003. Quality control in the endoplasmic reticulum. *Nat. Rev. Mol. Cell Biol.* 4, 181–191.
- Engelman, D.M., Steitz, T.A., 1981. The spontaneous insertion of proteins into and across membranes - the helical hairpin hypothesis. *Cell* 23, 411–422.
- Engelman, D.M., Chen, Y., Chin, C.N., Curran, A.R., Dixon, A.M., Dupuy, A.D., Lee, A.S., Lehnert, U., Matthews, E.E., Reshetnyak, Y.K., Senes, A., Popot, J.L., 2003. Membrane protein folding: beyond the two stage model. *FEBS Lett.* 555, 122–125.
- Farkas, A., Bohnsack, K.E., 2021. Capture and delivery of tail-anchored proteins to the endoplasmic reticulum. *JCB (J. Cell Biol.)* 220.
- Fernández, A., Berry, R.S., 2003. Proteins with H-bond packing defects are highly interactive with lipid bilayers: implications for amyloidogenesis. *Proc. Natl. Acad. Sci. U. S. A.* 100, 2391–2396.
- Ferreira, T.M., Sood, R., Bärenwald, R., Carlström, G., Topgaard, D., Saalwächter, K., Kinnunen, P.K.J., Ollila, O.H.S., 2016. Acyl chain disorder and azelaoyl orientation in lipid membranes containing oxidized lipids. *Langmuir* 32, 6524–6533.
- Fiedorczuk, K., Chen, J., 2022. Mechanism of CFTR correction by type I folding correctors. *Cell* 185, 158–168 e11.
- Fraser-Pitt, D., O'neil, D., 2015. Cystic fibrosis - a multiorgan protein misfolding disease. *Future Sci. OA* 1, FS057.
- Friedman, R., 2018. Membrane-ion interactions. *J. Membr. Biol.* 251, 453–460.
- Fusco, G., Chen, S.W., Williamson, P.T.F., Cascella, R., Perni, M., Jarvis, J.A., Cecchi, C., Vendruscolo, M., Chiti, F., Cremades, N., Ying, L.M., Dobson, C.M., De Simone, A., 2017. Structural basis of membrane disruption and cellular toxicity by  $\alpha$ -synuclein oligomers. *Science* 358, 1440.
- Gaschler, M.M., Stockwell, B.R., 2017. Lipid peroxidation in cell death. *Biochem. Biophys. Res. Commun.* 482, 419–425.
- Ge, Y., Draycheva, A., Bornemann, T., Rodnina, M.V., Wintermeyer, W., 2014. Lateral opening of the bacterial translocon on ribosome binding and signal peptide insertion. *Nat. Commun.* 5.
- Goemans, C., Denoncin, K., Collet, J.F., 2014. Folding mechanisms of periplasmic proteins. *Biochim. Biophys. Acta Mol. Cell Res.* 1843, 1517–1528.
- Graf, G.A., Cohen, J.C., Hobbs, H.H., 2004. Missense mutations in ABCG5 and ABCG8 disrupt heterodimerization and trafficking. *J. Biol. Chem.* 279, 24881–24888.

- Greenblatt, E.J., Olzmann, J.A., Kopito, R.R., 2011. Derlin-1 is a rhomboid pseudoprotease required for the dislocation of mutant  $\alpha$ -1 antitrypsin from the endoplasmic reticulum. *Nat. Struct. Mol. Biol.* 18, 1147–U115.
- Griciuc, A., Aron, L., Piccoli, G., Ueffing, M., 2010. Clearance of Rhodopsin(P23H) aggregates requires the ERAD effector VCP. *Biochim. Biophys. Acta* 1803, 424–434.
- Gu, Y.H., Li, H.Y., Dong, H.H., Zeng, Y., Zhang, Z.Y., Paterson, N.G., Stansfeld, P.J., Wang, Z.S., Zhang, Y.Z., Wang, W.J., Dong, C.J., 2016. Structural basis of outer membrane protein insertion by the BAM complex. *Nature* 531, 64.
- Guay, K.P., Chou, W.C., Canniff, N.P., Paul, K.B., Hebert, D.N., 2025. N-glycan-dependent protein maturation and quality control in the ER. *Nat. Rev. Mol. Cell Biol.*
- Guerrero, C.J., Brodsky, J.L., 2012. The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology. *Physiol. Rev.* 92, 537–576.
- Guixà-González, R., Albasanz, J.L., Rodríguez-Espigares, I., Pastor, M., Sanz, F., Martí-Solano, M., Manna, M., Martínez-Seara, H., Hildebrand, P.W., Martín, M., Selent, J., 2017. Membrane cholesterol access into a G-protein-coupled receptor. *Nat. Commun.* 8.
- Guo, L., Liu, G., He, J., Jia, X., He, Y., Wang, Z., Qian, H., 2025. Structural insights into the human HRD1 ubiquitin ligase complex. *Nat. Commun.* 16, 6007.
- Haeri, M., Knox, B.E., 2012. Rhodopsin mutant P23H destabilizes rod photoreceptor disk membranes. *PLoS One* 7.
- Hagan, C.L., Silhavy, T.J., Kahne, D., 2011. beta-Barrel membrane protein assembly by the bam complex. *Annu. Rev. Biochem.* 80, 189–210.
- Harris, N.J., Pellowe, G.A., Blackholly, L.R., Gulaidi-Breen, S., Findlay, H.E., Booth, P.J., 2022. Methods to study folding of alpha-helical membrane proteins in lipids. *Open Biol.* 12.
- Hartl, F.U., Bracher, A., Hayer-Hartl, M., 2011. Molecular chaperones in protein folding and proteostasis. *Nature* 475, 324–332.
- Hassdenteufel, S., Johnson, N., Paton, A.W., Paton, J.C., High, S., Zimmermann, R., 2018. Chaperone-mediated Sec61 channel gating during ER import of small precursor proteins overcomes Sec61 inhibitor-reinforced energy barrier. *Cell Rep.* 23, 1373–1386.
- Hedger, G., Koldso, H., Chavent, M., Siebold, C., Rohatgi, R., Sansom, M.S.P., 2019. Cholesterol interaction sites on the transmembrane domain of the hedgehog signal transducer and class F G protein-coupled receptor smoothened. *Structure* 27, 549–559 e2.
- Hegde, R.S., Keenan, R.J., 2011. Tail-anchored membrane protein insertion into the endoplasmic reticulum. *Nat. Rev. Mol. Cell Biol.* 12, 787–798.
- Hegde, R.S., Keenan, R.J., 2022. The mechanisms of integral membrane protein biogenesis. *Nat. Rev. Mol. Cell Biol.* 23, 107–124.
- Hegde, R.S., Keenan, R.J., 2024. A unifying model for membrane protein biogenesis. *Nat. Struct. Mol. Biol.* 31, 1009–1017.
- Helenius, A., Aebi, M., 2004. Roles of N-linked glycans in the endoplasmic reticulum. *Annu. Rev. Biochem.* 73, 1019–1049.
- Hermansen, S., Ryoo, D., Orwick-Rydmark, M., Saragliadis, A., Gumbart, J.C., Linke, D., 2022. The role of extracellular loops in the folding of outer membrane protein X (OmpX) of *Escherichia coli*. *Front. Mol. Biosci.* 9, 918480.
- Hessa, T., Kim, H., Bihlmaier, K., Lundin, C., Boekel, J., Andersson, H., Nilsson, I., White, S.H., Von Heijne, G., 2005. Recognition of transmembrane helices by the endoplasmic reticulum translocon. *Nature* 433, 377–381.
- Hetz, C., Zhang, K.Z., Kaufman, R.J., 2020. Mechanisms, regulation and functions of the unfolded protein response. *Nat. Rev. Mol. Cell Biol.* 21, 421–438.
- Holthuis, J.C., Menon, A.K., 2014. Lipid landscapes and pipelines in membrane homeostasis. *Nature* 510, 48–57.
- Hong, H., 2014. Toward understanding driving forces in membrane protein folding. *Arch. Biochem. Biophys.* 564, 297–313.
- Hong, H., 2015. Role of lipids in folding, misfolding and function of integral membrane proteins. *Adv. Exp. Med. Biol.* 855, 1–31.
- Hong, H.D., Tamm, L.K., 2004. Elastic coupling of integral membrane protein stability to lipid bilayer forces. *Proc. Natl. Acad. Sci. U. S. A.* 101, 4065–4070.
- Hong, H.D., Park, S., Jiménez, R.H.F., Rinehart, D., Tamm, L.K., 2007. Role of aromatic side chains in the folding and thermodynamic stability of integral membrane proteins. *J. Am. Chem. Soc.* 129, 8320–8327.
- Hong, H., Joh, N.H., Bowie, J.U., Tamm, L.K., 2009. Methods for measuring the thermodynamic stability of membrane proteins. *Methods Enzymol.: Biothermodynamics* 455, 213–236. Part A, 455.
- Horne, J.E., Brockwell, D.J., Radford, S.E., 2020. Role of the lipid bilayer in outer membrane protein folding in Gram-negative bacteria. *J. Biol. Chem.* 295, 10340–10367.
- Hrmova, M., 2024. Quaternary arrangements of membrane proteins: an aquaporin case. *Biochem. Soc. Trans.* 52, 2557–2568.
- Huang, Y., Cavanaugh, A., Breitwieser, G.E., 2011. Regulation of stability and trafficking of calcium-sensing receptors by pharmacologic chaperones. *Adv. Pharmacol.* 62, 143–173.
- Huang, H., Kuenze, G., Smith, J.A., Taylor, K.C., Duran, A.M., Hadziselimovic, A., Meiler, J., Vanoye, C.G., George, A.L., Sanders, C.R., 2018. Mechanisms of KCNQ1 channel dysfunction in long QT syndrome involving voltage sensor domain mutations. *Sci. Adv.* 4, eaar2631.
- Huber, M.E., Toy, L., Schmidt, M.F., Vogt, H., Budzinski, J., Wiefhoff, M.F.J., Merten, N., Kostenis, E., Weikert, D., Schiedel, M., 2022. A chemical biology toolbox targeting the intracellular binding site of CCR9: fluorescent ligands, new drug leads and PROTACs. *Angew Chem. Int. Ed.* 61, e202116782.
- Hunte, C., 2005. Specific protein-lipid interactions in membrane proteins. *Biochem. Soc. Trans.* 33, 938–942.
- Iling, M.E., Rajan, R.S., Bence, N.F., Kopito, R.R., 2002. A rhodopsin mutant linked to autosomal dominant retinitis pigmentosa is prone to aggregate and interacts with the ubiquitin proteasome system. *J. Biol. Chem.* 277, 34150–34160.
- Itaya, H., Kasahara, K., Xie, Q., Yano, Y., Matsuzaki, K., Takahashi, T., 2021. All-atom molecular dynamics elucidating molecular mechanisms of single-transmembrane model peptide dimerization in a lipid bilayer. *ACS Omega* 6, 11458–11465.
- Ito, K., Akiyama, Y., 2005. Cellular functions, mechanism of action, and regulation of FtsH protease. *Annu. Rev. Microbiol.* 59, 211–231.
- Janoschke, M., Zimmermann, M., Brunauer, A., Humbel, R., Junne, T., Spiess, M., 2021. Efficient integration of transmembrane domains depends on the folding properties of the upstream sequences. *Proc. Natl. Acad. Sci. U. S. A.* 118.
- Janovick, J.A., Maya-Nunez, G., Conn, P.M., 2002. Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target. *J. Clin. Endocrinol. Metab.* 87, 3255–3262.
- Janovick, J.A., Goulet, M., Bush, E., Greer, J., Wettlaufer, D.G., Conn, P.M., 2003. Structure-activity relations of successful pharmacologic chaperones for rescue of naturally occurring and manufactured mutants of the gonadotropin-releasing hormone receptor. *J. Pharmacol. Exp. Therapeut.* 305, 608–614.
- Janovick, J.A., Patny, A., Mosley, R., Goulet, M.T., Altman, M.D., Rush, T.S., Cornea, A., Conn, P.M., 2009. Molecular mechanism of action of pharmacoperone rescue of misrouted GPCR mutants: the GnRH receptor. *Mol. Endocrinol.* 23, 157–168.
- Jarerattanachai, V., Karttunen, M., Wong-Ekkabut, J., 2013. Molecular dynamics study of oxidized lipid bilayers in NaCl solution. *J. Phys. Chem. B* 117, 8490–8501.
- Javadpour, M.M., Eilers, M., Groesbeek, M., Smith, S.O., 1999. Helix packing in polytopic membrane proteins: role of glycine in transmembrane helix association. *Biophys. J.* 77, 1609–1618.
- Jensen, M.O., Mouritsen, O.G., 2004. Lipids do influence protein function - the hydrophobic matching hypothesis revisited. *Biochim. Biophys. Acta Biomembr.* 1666, 205–226.
- Jensen, M.O., Tajkhorshid, E., Schulten, K., 2003. Electrostatic tuning of permeation and selectivity in aquaporin water channels. *Biophys. J.* 85, 2884–2899.
- Jentsch, T.J., Pusch, M., 2018. CLC chloride channels and transporters: structure, function, physiology, and disease. *Physiol. Rev.* 98, 1493–1590.
- Joazeiro, C.a.P., 2019. Mechanisms and functions of ribosome-associated protein quality control. *Nat. Rev. Mol. Cell Biol.* 20, 368–383.
- Jurkiewicz, P., Olzyska, A., Cwiklik, L., Conte, E., Jungwirth, P., Megli, F.M., Hof, M., 2012. Biophysics of lipid bilayers containing oxidatively modified phospholipids: insights from fluorescence and EPR experiments and from MD simulations. *Biochim. Biophys. Acta Biomembr.* 1818, 2388–2402.
- Kandasamy, S.K., Larson, R.G., 2006. Molecular dynamics simulations of model trans-membrane peptides in lipid bilayers: a systematic investigation of hydrophobic mismatch. *Biophys. J.* 90, 2326–2343.
- Karagöz, G.E., Acosta-Alvear, D., Walter, P., 2019. The unfolded protein response: detecting and responding to fluctuations in the protein-folding capacity of the endoplasmic reticulum. *Cold Spring Harbor Perspect. Biol.* 11.
- Karathanou, K., Bondar, A.N., 2018. Dynamic water hydrogen-bond networks at the interface of a lipid membrane containing palmitoyl-oleoyl phosphatidylglycerol. *J. Membr. Biol.* 251, 461–473.

- Keen, A.C., Jorg, M., Halls, M.L., 2024. The application of targeted protein degradation technologies to G protein-coupled receptors. *Br. J. Pharmacol.* 181, 2351–2358.
- Khemaissa, S., Sagan, S., Walrant, A., 2021. Tryptophan, an amino-acid endowed with unique properties and its many roles in membrane proteins. *Crystals* 11.
- Killian, J.A., 1998. Hydrophobic mismatch between proteins and lipids in membranes. *Biochim. Biophys. Acta Rev. Biomembr.* 1376, 401–416.
- Killian, J.A., Von Heijne, G., 2000. How proteins adapt to a membrane-water interface. *Trends Biochem. Sci.* 25, 429–434.
- Kim, E., Min, D., 2023. Chaperoning the major facilitator superfamily at single-molecule level. *Structure* 31, 1291–1294.
- Kim, S., Lee, D., Wijesinghe, W.C.B., Min, D., 2023. Robust membrane protein tweezers reveal the folding speed limit of helical membrane proteins. *eLife* 12.
- Kim, S.A., Kim, H.G., Wijesinghe, W.C.B., Min, D., Yoon, T.Y., 2025. Emerging patterns in membrane protein folding pathways. *Annu. Rev. Biophys.* 54, 141–162.
- Kleinschmidt, J.H., 2015. Folding of  $\beta$ -barrel membrane proteins in lipid bilayers - unassisted and assisted folding and insertion. *Biochim. Biophys. Acta Biomembr.* 1848, 1927–1943.
- Klose, C.J., Meighen-Berger, K.M., Kulke, M., Parr, M., Steigenberger, B., Zacharias, M., Frishman, D., Feige, M.J., 2025. The EMC acts as a chaperone for membrane proteins. *Nat. Commun.* 16.
- Knyazev, D.G., Kuttner, R., Zimmermann, M., Sobakinskaya, E., Pohl, P., 2018. Driving forces of translocation through bacterial translocon SecYEG. *J. Membr. Biol.* 251, 329–343.
- Kocan, M., See, H.B., Sampaio, N.G., Eidne, K.A., Feldman, B.J., Pfleger, K.D., 2009. Agonist-independent interactions between beta-arrestins and mutant vasopressin type II receptors associated with nephrogenic syndrome of inappropriate antidiuresis. *Mol. Endocrinol.* 23, 559–571.
- Krainer, G., Treff, A., Hartmann, A., Stone, T.A., Schenkel, M., Keller, S., Deber, C.M., Schlierf, M., 2018. A minimal helical-hairpin motif provides molecular-level insights into misfolding and pharmacological rescue of CFTR. *Commun. Biol.* 1.
- Krogh, A., Larsson, B., Von Heijne, G., Sonnhammer, E.L., 2001. Predicting transmembrane protein topology with a hidden markov model: application to complete genomes. *J. Mol. Biol.* 305, 567–580.
- Kruse, A.C., Ring, A.M., Manglik, A., Hu, J., Hu, K., Eitel, K., Hubner, H., Pardon, E., Valant, C., Sexton, P.M., Christopoulos, A., Felder, C.C., Gmeiner, P., Steyaert, J., Weis, W.I., Garcia, K.C., Wess, J., Kobilka, B.K., 2013. Activation and allosteric modulation of a muscarinic acetylcholine receptor. *Nature* 504, 101–106.
- Kubisch, C., Schmidt-Rose, T., Fontaine, B., Bretag, A.H., Jentsch, T.J., 1998. CIC-1 chloride channel mutations in myotonia congenita: variable penetrance of mutations shifting the voltage dependence. *Hum. Mol. Genet.* 7, 1753–1760.
- Kurzawa-Akanbi, M., Tammireddy, S., Fabrik, I., Doherty, M.K., Heap, R., Burmann, B.M., Trost, M., Lucocq, J.M., Gherman, A., Fairfoul, G., Singh, P., Burté, F., Green, A., Mckeith, I.G., Härtlova, A., Whitfield, P.D., Morris, C.M., Gliadelyte, L., Matetko-Burmann, I., 2021. Altered ceramide metabolism is a feature in the extracellular vesicle-mediated spread of alpha-synuclein in lewy body disorders. *Acta Neuropathol.* 142, 961–984.
- Laganowsky, A., Reading, E., Allison, T.M., Ulmschneider, M.B., Degiacomi, M.T., Baldwin, A.J., Robinson, C.V., 2014. Membrane proteins bind lipids selectively to modulate their structure and function. *Nature* 510, 172.
- Lai, Y., Zhao, C.Y., Tian, Z.Q., Wang, C.C., Fan, J.Q., Hu, X., Tu, J., Li, T.H., Leitz, J., Pfuetzner, R.A., Liu, Z.T., Zhang, S.N., Su, Z.M., Burré, J., Li, D., Südhof, T.C., Zhu, Z.J., Liu, C., Brunger, A.T., Diao, J.J., 2023. Neutral lysophosphatidylcholine mediates  $\alpha$ -synuclein-induced synaptic vesicle clustering. *Proc. Natl. Acad. Sci. U. S. A* 120.
- Lamprakis, C., Andreadelis, I., Manchester, J., Velez-Vega, C., Duca, J.S., Cournia, Z., 2021. Evaluating the efficiency of the martini force field to study protein dimerization in aqueous and membrane environments. *J. Chem. Theor. Comput.* 17, 3088–3102.
- Lashuel, H.A., Hartley, D., Petre, B.M., Walz, T., Lansbury, P.T., 2002. Neurodegenerative disease - amyloid pores from pathogenic mutations. *Nature* 418, 291–291.
- Lee, A.G., 2004. How lipids affect the activities of integral membrane proteins. *Biochim. Biophys. Acta Biomembr.* 1666, 62–87.
- Leidenheimer, N.J., Ryder, K.G., 2014. Pharmacological chaperoning: a primer on mechanism and pharmacology. *Pharmacol. Res.* 83, 10–19.
- Levental, I., Lyman, E., 2023. Regulation of membrane protein structure and function by their lipid nano-environment (Sept, 10.1038/s41580022-00524-4, 2022). *Nat. Rev. Mol. Cell Biol.* 24, 79–79.
- Lewis, A.J.O., Zhong, F., Keenan, R.J., Hegde, R.S., Frost, A., 2024. Structural analysis of the dynamic ribosome-translocon complex. *eLife* 13.
- Li, F., Egea, P.F., Vecchio, A.J., Asial, I., Gupta, M., Paulino, J., Bajaj, R., Dickinson, M.S., Ferguson-Miller, S., Monk, B.C., Stroud, R.M., 2021. Highlighting membrane protein structure and function: a celebration of the protein data bank. *J. Biol. Chem.* 296.
- Lilley, B.N., Ploegh, H.L., 2004. A membrane protein required for dislocation of misfolded proteins from the ER. *Nature* 429, 834–840.
- Lima, D.C.A., Volpe Bossa, G., Ciancaglini, P., Ramos, A.P., Soares, T.A., 2025. The effect of ceramide ratio on the membrane curvature of mimetic models of matrix vesicles. *ACS Phys. Chem. Au* 5, 456–466.
- Linxweiler, M., Schick, B., Zimmermann, R., 2017. Let's talk about Secs: Sec61, Sec62 and Sec63 in signal transduction, oncology and personalized medicine. *Signal Transduct. Targeted Ther.* 2.
- Liu, M., Dudley, S.C., 2018. The role of the unfolded protein response in arrhythmias. *Channels* 12, 335–345.
- Liu, L., Komatsu, H., Murray, I.V.J., Axelsen, P.H., 2008. Promotion of amyloid  $\beta$  protein misfolding and fibrillogenesis by a lipid oxidation product. *J. Mol. Biol.* 377, 1236–1250.
- Logothetis, D.E., Jin, T., Lupyán, D., Rosenhouse-Dantsker, A., 2007. Phosphoinositide-mediated gating of inwardly rectifying K(+) channels. *Pflügers Archiv* 455, 83–95.
- Lukacs, G.L., Verkman, A.S., 2012. CFTR: folding, misfolding and correcting the  $\Delta$ F508 conformational defect. *Trends Mol. Med.* 18, 81–91.
- Lundbaek, J.A., Andersen, O.S., Werge, T., Nielsen, C., 2003. Cholesterol-induced protein sorting: an analysis of energetic feasibility. *Biophys. J.* 84, 2080–2089.
- Ma, Z., Zhou, J., 2025. NDA submission of vepdegestrant (ARV-471) to U.S. FDA: the beginning of a new era of PROTAC degraders. *J. Med. Chem.* 68, 14129–14136.
- Maccallum, J.L., Bennett, W.F., Tieleman, D.P., 2008. Distribution of amino acids in a lipid bilayer from computer simulations. *Biophys. J.* 94, 3393–3404.
- Machin, J.M., Kalli, A.C., Ranson, N.A., Radford, S.E., 2023. Protein-lipid charge interactions control the folding of outer membrane proteins into asymmetric membranes. *Nat. Chem.* 15, 1754–.
- Mackenzie, K.R., 2006. Folding and stability of  $\alpha$ -helical integral membrane proteins. *Chem. Rev.* 106, 1931–1977.
- Marinko, J.T., Huang, H., Penn, W.D., Capra, J.A., Schleich, J.P., Sanders, C.R., 2019. Folding and misfolding of human membrane proteins in health and disease: from single molecules to cellular proteostasis. *Chem. Rev.* 119, 5537–5606.
- Marsh, D., 2008. Protein modulation of lipids, and vice-versa, in membranes. *Biochim. Biophys. Acta* 1778, 1545–1575.
- Melcrová, A., Pokorna, S., Pullanchery, S., Kohagen, M., Jurkiewicz, P., Hof, M., Jungwirth, P., Cremer, P.S., Cwiklik, L., 2016. The complex nature of calcium cation interactions with phospholipid bilayers. *Sci. Rep.* 6.
- Mendes, H.F., Cheetham, M.E., 2008. Pharmacological manipulation of gain-of-function and dominant-negative mechanisms in rhodopsin retinitis pigmentosa. *Hum. Mol. Genet.* 17, 3043–3054.
- Mendre, C., Mouillac, B., 2010. [Pharmacological chaperones: a potential therapeutic treatment for conformational diseases]. *Med. Sci.* 26, 627–635.
- Merdanovic, M., Clausen, T., Kaiser, M., Huber, R., Ehrmann, M., 2011. Protein quality control in the bacterial periplasm. *Annu. Rev. Microbiol.* 65, 149–168.
- Meyer, C., Arizzi, A., Henson, T., Aviran, S., Longo, M.L., Wang, A.J., Tan, C.M., 2025. Designer artificial environments for membrane protein synthesis. *Nat. Commun.* 16.
- Milligan, G., Ward, R.J., Marsango, S., 2019. GPCR homo-oligomerization. *Curr. Opin. Cell Biol.* 57, 40–47.
- Min, D., 2024. Folding speeds of helical membrane proteins. *Biochem. Soc. Trans.* 52, 491–501.
- Min, D., Jefferson, R.E., Bowie, J.U., Yoon, T.Y., 2015. Mapping the energy landscape for second-stage folding of a single membrane protein. *Nat. Chem. Biol.* 11, 981–987.
- Min, D., Jefferson, R.E., Qi, Y., Wang, J.Y., Arbing, M.A., Im, W., Bowie, J.U., 2018. Unfolding of a CIC chloride transporter retains memory of its evolutionary history. *Nat. Chem. Biol.* 14, 489–496.
- Mirdha, L., 2024. Aggregation behavior of amyloid beta peptide depends upon the membrane lipid composition. *J. Membr. Biol.* 257, 151–164.
- Moon, C.P., Fleming, K.G., 2011. Side-chain hydrophobicity scale derived from transmembrane protein folding into lipid bilayers. *Proc. Natl. Acad. Sci. U. S. A* 108, 10174–10177.
- Morello, J.P., Petaja-Repo, U.E., Bichet, D.G., Bouvier, M., 2000a. Pharmacological chaperones: a new twist on receptor folding. *Trends Pharmacol. Sci.* 21, 466–469.

- Morello, J.P., Salahpour, A., Laperriere, A., Bernier, V., Arthus, M.F., Lonergan, M., Petaja-Repo, U., Angers, S., Morin, D., Bichet, D.G., Bouvier, M., 2000b. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. *J. Clin. Investig.* 105, 887–895.
- Mu, T.W., Ong, D.S., Wang, Y.J., Balch, W.E., Yates, J. R., 3rd, Segatori, L., Kelly, J.W., 2008. Chemical and biological approaches synergize to ameliorate protein-folding diseases. *Cell* 134, 769–781.
- Mukhaleva, E., Yang, T., Sadler, F., Sivaramakrishnan, S., Ma, N., Vaidehi, N., 2024. Cellular lipids regulate the conformational ensembles of the disordered intracellular loop 3 in beta2-adrenergic receptor. *iScience* 27, 110086.
- Mullard, A., 2019. First targeted protein degrader hits the clinic. *Nat. Rev. Drug Discov.*
- Mullard, A., 2021. Targeted protein degraders crowd into the clinic. *Nat. Rev. Drug Discov.* 20, 247–250.
- Muller, M.P., Jiang, T., Sun, C., Lihan, M., Pant, S., Mahinthichaichan, P., Trifan, A., Tajkhorshid, E., 2019. Characterization of lipid-protein interactions and lipid-mediated modulation of membrane protein function through molecular simulation. *Chem. Rev.* 119, 6086–6161.
- Murzin, A.G., Lesk, A.M., Chothia, C., 1994. Principles determining the structure of beta-sheet barrels in proteins .1. A theoretical-analysis. *J. Mol. Biol.* 236, 1369–1381.
- Nagle, J.F., Tristram-Nagle, S., 2000. Structure of lipid bilayers. *Biochim. Biophys. Acta Rev. Biomembr.* 1469, 159–195.
- Ni, C.X., Hong, M., 2024. Oligomerization of drug transporters: forms, functions, and mechanisms. *Acta Pharm. Sin. B* 14, 1924–1938.
- Nicolson, G.L., 2014. The fluid-mosaic model of membrane structure: still relevant to understanding the structure, function and dynamics of biological membranes after more than 40 years. *Biochim. Biophys. Acta Biomembr.* 1838, 1451–1466.
- Nicolson, G.L., De Mattos, G.F., 2022. Fifty years of the fluid-mosaic model of biomembrane structure and organization and its importance in biomedicine with particular emphasis on membrane lipid replacement. *Biomedicines* 10.
- Nicolaus, F., Metola, A., Mermans, D., Liljenström, A., Krc, A., Abdullahi, S.M., Zimmer, M., Miller, T.F., Von Heijne, G., 2021. Residue-by-residue analysis of cotranslational membrane protein integration in vivo. *eLife* 10.
- Noinaj, N., Kuszak, A.J., Gumbart, J.C., Lukacik, P., Chang, H.S., Easley, N.C., Lithgow, T., Buchanan, S.K., 2013. Structural insight into the biogenesis of  $\beta$ -barrel membrane proteins. *Nature* 501, 385.
- Noinaj, N., Rollauer, S.E., Buchanan, S.K., 2015. The  $\beta$ -barrel membrane protein insertase machinery from Gram-negative bacteria. *Curr. Opin. Struct. Biol.* 31, 35–42.
- Noinaj, N., Gumbart, J.C., Buchanan, S.K., 2017. The beta-barrel assembly machinery in motion. *Nat. Rev. Microbiol.* 15, 197–204.
- Noorwez, S.M., Malhotra, R., Mcdowell, J.H., Smith, K.A., Krebs, M.P., Kaushal, S., 2004. Retinoids assist the cellular folding of the autosomal dominant retinitis pigmentosa opsin mutant P23H. *J. Biol. Chem.* 279, 16278–16284.
- Notti, R.Q., Walz, T., 2022. Native-like environments afford novel mechanistic insights into membrane proteins. *Trends Biochem. Sci.* 47, 561–569.
- Okiyonedo, T., Apaja, P.M., Lukacs, G.L., 2011. Protein quality control at the plasma membrane. *Curr. Opin. Cell Biol.* 23, 483–491.
- Oram, J.F., Vaughan, A.M., 2006. ATP-binding cassette cholesterol transporters and cardiovascular disease. *Circ. Res.* 99, 1031–1043.
- Orhan, G., Bock, M., Schepers, D., Ilina, E.I., Reichel, S.N., Löffler, H., Jezutkovic, N., Weckhuysen, S., Mandelstam, S., Suls, A., Danker, T., Guenther, E., Scheffer, I.E., De Jonghe, P., Lerche, H., Maljevic, S., 2014. Dominant-negative effects of KCNQ2 mutations are associated with epileptic encephalopathy. *Ann. Neurol.* 75, 382–394.
- Osborne, A.R., Rapoport, T.A., Van Den Berg, B., 2005. Protein translocation by the Sec61/SecY channel. *Annu. Rev. Cell Dev. Biol.* 21, 529–550.
- Otero, J.H., Lizák, B., Hendershot, L.M., 2010. Life and death of a BiP substrate. *Semin. Cell Dev. Biol.* 21, 472–478.
- Pali, T., Marsh, D., 2001. Tilt, twist, and coiling in beta-barrel membrane proteins: relation to infrared dichroism. *Biophys. J.* 80, 2789–2797.
- Pan, J.J., Mills, T.T., Tristram-Nagle, S., Nagle, J.F., 2008. Cholesterol perturbs lipid bilayers nonuniversally. *Phys. Rev. Lett.* 100.
- Pan, J.J., Tristram-Nagle, S., Nagle, J.F., 2009. Effect of cholesterol on structural and mechanical properties of membranes depends on lipid chain saturation. *Phys. Rev.* 80.
- Paradies, G., Paradies, V., Ruggiero, F.M., Petrosillo, G., 2014a. Cardiolipin and mitochondrial function in health and disease. *Antioxidants Redox Signal.* 20, 1925–1953.
- Paradies, G., Paradies, V., Ruggiero, F.M., Petrosillo, G., 2014b. Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease. *World J. Gastroenterol.* 20, 14205–14218.
- Parmar, V.K., Grinde, E., Mazurkiewicz, J.E., Herrick-Davis, K., 2017. Beta(2)-adrenergic receptor homodimers: role of transmembrane domain 1 and helix 8 in dimerization and cell surface expression. *Biochim. Biophys. Acta Biomembr.* 1859, 1445–1455.
- Pasenkiewicz-Gierula, M., Baczyński, K., Markiewicz, M., Murzyn, K., 2016. Computer modelling studies of the bilayer/water interface. *Biochim. Biophys. Acta* 1858, 2305–2321.
- Pastlowski, W., Lillelund, O.K., Kristensen, J.V., Schafer, N.P., Baker, R.P., Urban, S., Otzen, D.E., 2015. Cooperative folding of a polytopic alpha-helical membrane protein involves a compact N-terminal nucleus and nonnative loops. *Proc. Natl. Acad. Sci. U. S. A.* 112, 7978–7983.
- Pechmann, S., Chartron, J.W., Frydman, J., 2014. Local slowdown of translation by nonoptimal codons promotes nascent-chain recognition by SRP. *Nat. Struct. Mol. Biol.* 21, 1100–1105.
- Peruzzi, J.A., Steinkühler, J., Vu, T.Q., Gunnels, T.F., Hu, V.T., Lu, P.L., Baker, D., Kamat, N.P., 2024. Hydrophobic mismatch drives self-organization of designer proteins into synthetic membranes. *Nat. Commun.* 15.
- Pfeiffer, K., Gohil, V., Stuart, R.A., Hunte, C., Brandt, U., Greenberg, M.L., Schägger, H., 2003. Cardiolipin stabilizes respiratory chain supercomplexes. *J. Biol. Chem.* 278, 52873–52880.
- Phillips, R., Ursell, T., Wiggins, P., Sens, P., 2009. Emerging roles for lipids in shaping membrane-protein function. *Nature* 459, 379–385.
- Pleiner, T., Tomaleri, G.P., Januszyk, K., Inglis, A.J., Hazu, M., Voorhees, R.M., 2020. Structural basis for membrane insertion by the human ER membrane protein complex. *Science* 369, 433–436.
- Popot, J.L., Engelman, D.M., 1990. Membrane protein folding and oligomerization: the two-stage model. *Biochemistry* 29, 4031–4037.
- Powell, C.E., Gao, Y., Tan, L., Donovan, K.A., Nowak, R.P., Loehr, A., Bahcall, M., Fischer, E.S., Janne, P.A., George, R.E., Gray, N.S., 2018. Chemically induced degradation of anaplastic lymphoma kinase (ALK). *J. Med. Chem.* 61, 4249–4255.
- Pruitt, M.M., Lamm, M.H., Coffman, C.R., 2013. Molecular dynamics simulations on the Tre1 G protein-coupled receptor: exploring the role of the arginine of the NRY motif in Tre1 structure. *BMC Struct. Biol.* 13.
- Puig, B., Altmepfen, H., Glatzel, M., 2014. The GPI-anchoring of PrP: implications in sorting and pathogenesis. *Prion* 8, 11–18.
- Quirós, P.M., Langer, T., López-Otín, C., 2015. New roles for mitochondrial proteases in health, ageing and disease. *Nat. Rev. Mol. Cell Biol.* 16, 345–359.
- Rao, B., Wang, Q., Yao, D., Xia, Y., Li, W., Xie, Y., Li, S., Cao, M., Shen, Y., Qin, A., Zhao, J., Cao, Y., 2023. The cryo-EM structure of the human ERAD retrotranslocation complex. *Sci. Adv.* 9, eadi5656.
- Reggiori, F., Molinari, M., 2022. Er-phagy: mechanisms, regulation, and diseases connected to the lysosomal clearance of the endoplasmic reticulum. *Physiol. Rev.* 102, 1393–1448.
- Reh, C.M.S., Hendy, G.N., Cole, D.E.C., Jeandron, D.D., 2011. Neonatal hyperparathyroidism with a heterozygous calcium-sensing receptor (CASR) R185Q mutation: clinical benefit from cinacalcet. *J. Clin. Endocrinol. Metabol.* 96, E707–E712.
- Renne, M.F., Ernst, R., 2023. Membrane homeostasis beyond fluidity: control of membrane compressibility. *Trends Biochem. Sci.* 48, 963–977.
- Rinne, S., Kiper, A.K., Schlichthor, G., Dittmann, S., Netter, M.F., Limberg, S.H., Silbernagel, N., Zuzarte, M., Moosdorf, R., Wulf, H., Schulze-Bahr, E., Rolfes, C., Decher, N., 2015. TASK-1 and TASK-3 may form heterodimers in human atrial cardiomyocytes. *J. Mol. Cell. Cardiol.* 81, 71–80.
- Rinne, S., Schick, F., Vowinkel, K., Schutte, S., Krasel, C., Kaufenstein, S., Schafer, M.K., Kiper, A.K., Muller, T., Decher, N., 2024. Potassium channel TASK-5 forms functional heterodimers with TASK-1 and TASK-3 to break its silence. *Nat. Commun.* 15, 7548.
- Robben, J.H., Sze, M., Knoers, N.V., Deen, P.M., 2007. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus. *Am. J. Physiol. Ren. Physiol.* 292, F253–F260.
- Rog, T., Pasenkiewicz-Gierula, M., Vattulainen, I., Karttunen, M., 2009. Ordering effects of cholesterol and its analogues. *Biochim. Biophys. Acta* 1788, 97–121.



- Romo, T.D., Grossfield, A., Pitman, M.C., 2010. Concerted interconversion between ionic lock substates of the  $\beta$  adrenergic receptor revealed by microsecond timescale molecular dynamics. *Biophys. J.* 98, 76–84.
- Ruffilli, C., Roth, S., Zelcer, N., Moreau, K., 2025. Orthogonal validation of PROTAC mediated degradation of the integral membrane proteins EGFR and c-MET. *Sci. Rep.* 15, 504.
- Rugarli, E.I., Langer, T., 2012. Mitochondrial quality control: a matter of life and death for neurons. *EMBO J.* 31, 1336–1349.
- Ruggiano, A., Foresti, O., Carvalho, P., 2014. ER-associated degradation: protein quality control and beyond. *JCB (J. Cell Biol.)* 204, 868–878.
- Ruiz, N., Kahne, D., Silhavy, T.J., 2006. Advances in understanding bacterial outer-membrane biogenesis. *Nat. Rev. Microbiol.* 4, 57–66.
- Runas, K.A., Malmstadt, N., 2015. Low levels of lipid oxidation radically increase the passive permeability of lipid bilayers. *Soft Matter* 11, 499–505.
- Ruprecht, J.J., Hellawell, A.M., Harding, M., Crichton, P.G., Mccoy, A.J., Kunji, E.R., 2014. Structures of yeast mitochondrial ADP/ATP carriers support a domain-based alternating-access transport mechanism. *Proc. Natl. Acad. Sci. U. S. A.* 111, E426–E434.
- Russo, A., 2020. Understanding the mammalian TRAP complex function(s). *Open Biol.* 10.
- Russ, W.P., Engelman, D.M., 2000. The GxxxG motif: a framework for transmembrane helix-helix association. *J. Mol. Biol.* 296, 911–919.
- Sadongo, V.W., Kim, E., Kim, S., Wijesinghe, W.C.B., Lee, T., Choi, J.M., Min, D., 2025. Single-molecule tweezers decode hidden dimerization patterns of membrane proteins within lipid bilayers. *Nat. Commun.* 16, 7366.
- Sakami, S., Kolesnikov, A.V., Kefalov, V.J., Palczewski, K., 2014. P23H opsin knock-in mice reveal a novel step in retinal rod disc morphogenesis. *Hum. Mol. Genet.* 23, 1723–1741.
- Sakamoto, K.M., Kim, K.B., Kumagai, A., Mercurio, F., Crews, C.M., Deshaies, R.J., 2001. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. *Proc. Natl. Acad. Sci. U. S. A.* 98, 8554–8559.
- Saliba, R.S., Munro, P.M.G., Luthert, P.J., Cheetham, M.E., 2002. The cellular fate of mutant rhodopsin: quality control, degradation and aggresome formation. *J. Cell Sci.* 115, 2907–2918.
- Sánchez, W.N., Driessen, A.J.M., Wilson, C.A.M., 2025. Protein targeting to the ER membrane: multiple pathways and shared machinery. *Crit. Rev. Biochem. Mol. Biol.* 60, 33–79.
- Santos, R., Ursu, O., Gaulton, A., Bento, A.P., Donadi, R.S., Bologa, C.G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T.I., Overington, J.P., 2017. A comprehensive map of molecular drug targets. *Nat. Rev. Drug Discov.* 16, 19–34.
- Sato, S., Ward, C.L., Krouse, M.E., Wine, J.J., Kopito, R.R., 1996. Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. *J. Biol. Chem.* 271, 635–638.
- Sato, T., Diehl, T.S., Narayanan, S., Funamoto, S., Ihara, Y., De Strooper, B., Steiner, H., Haass, C., Wolfe, M.S., 2007. Active  $\gamma$ -secretase complexes contain only one of each component. *J. Biol. Chem.* 282, 33985–33993.
- Schlame, M., Greenberg, M.L., 2017. Biosynthesis, remodeling and turnover of mitochondrial cardiolipin. *Biochim. Biophys. Acta Mol. Cell Biol. Lipids* 1862, 3–7.
- Schleiff, E., Soll, J., 2005. Membrane protein insertion: mixing eukaryotic and prokaryotic concepts. *EMBO Rep.* 6, 1023–1027.
- Schoebel, S., Mi, W., Stein, A., Ovchinnikov, S., Pavlovicz, R., Dimaio, F., Baker, D., Chambers, M.G., Su, H.Y., Li, D.S., Rapoport, T.A., Liao, M.F., 2017. Cryo-EM structure of the protein-conducting ERAD channel Hrd1 in complex with Hrd3. *Nature* 548, 352.
- Scott, C., Ioannou, Y.A., 2004. The NPC1 protein: structure implies function. *Biochim. Biophys. Acta* 1685, 8–13.
- Selivanovitch, E., Ostwalt, A., Chao, Z.M., Daniel, S., 2024. Emerging designs and applications for biomembrane biosensors. *Annu. Rev. Anal. Chem.* 17, 339–366.
- Senoo, N., Chinthapalli, D.K., Baile, M.G., Golla, V.K., Saha, B., Oluwole, A.O., Ogunbona, O.B., Saba, J.A., Munteanu, T., Valdez, Y., Whited, K., Sheridan, M.S., Chorev, D., Alder, N.N., May, E.R., Robinson, C., Claypool, S.M., 2024. Functional diversity among cardiolipin binding sites on the mitochondrial ADP/ATP carrier. *EMBO J.* 43, 2979–3008.
- Sergejevs, N., Carvalho, P., 2025. Mechanisms of transmembrane domain recognition during endoplasmic reticulum quality control. *Curr. Opin. Cell Biol.* 96, 102580.
- Sheikh, A.M., Nagai, A., 2011. Lysophosphatidylcholine modulates fibril formation of amyloid beta peptide. *FEBS J.* 278, 634–642.
- Shen, J., Kelleher, R.J., 2007. The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. *Proc. Natl. Acad. Sci. U. S. A.* 104, 403–409.
- Shurtleff, M.J., Itzhalet, D.N., Hussmann, J.A., Oakdale, N.T.S., Costa, E.A., Jonikas, M., Weibezahn, J., Popova, K.D., Jan, C.H., Sinitcyn, P., Vembar, S.S., Hernandez, H., Cox, J., Burlingame, A.L., Brodsky, J., Frost, A., Borner, G.H.H., Weissman, J.S., 2018. The ER membrane protein complex interacts cotranslationally to enable biogenesis of multipass membrane proteins. *eLife* 7.
- Sikdar, S., Banerjee, M., Vemparala, S., 2021. Effect of cholesterol on the membrane partitioning dynamics of hepatitis A virus-2B peptide. *Soft Matter* 17, 7963–7977.
- Silhavy, T.J., Kahne, D., Walker, S., 2010. The bacterial cell envelope. *Cold Spring Harbor Perspect. Biol.* 2.
- Singer, S.J., Nicolson, G.L., 1972. The fluid mosaic model of the structure of cell membranes. *Science* 175, 720.
- Sklar, J.G., Wu, T., Kahne, D., Silhavy, T.J., 2007. Defining the roles of the periplasmic chaperones SurA, Skp, and DegP in *Escherichia coli*. *Genes Dev.* 21, 2473–2484.
- Sleno, R., Hébert, T.E., 2018. The dynamics of GPCR oligomerization and their functional consequences. *G Protein-Coupled Receptors: Emerging Paradigms in Activation, Signaling and Regulation*, Pt A 338, 141–171.
- Smalinskaite, L., Hegde, R.S., 2023. The biogenesis of multipass membrane proteins. *Cold Spring Harbor Perspect. Biol.* 15.
- Srivastava, S.R., Zadafiya, P., Mahalakshmi, R., 2018. Hydrophobic mismatch modulates stability and plasticity of human mitochondrial VDAC2. *Biophys. J.* 115, 2386–2394.
- Steinkuhler, J., Jacobs, M.L., Boyd, M.A., Villaseñor, C.G., Loverde, S.M., Kamat, N.P., 2022. PEO-b-PBD diblock copolymers induce packing defects in lipid/hybrid membranes and improve insertion rates of natively folded peptides. *Biomacromolecules* 23, 4756–4765.
- Strandberg, E., Killian, J.A., 2003. Snorkeling of lysine side chains in transmembrane helices: how easy can it get? *FEBS Lett.* 544, 69–73.
- Suh, B.C., Hille, B., 2005. Regulation of ion channels by phosphatidylinositol 4,5-bisphosphate. *Curr. Opin. Neurobiol.* 15, 370–378.
- Sundaram, A., Yamsek, M., Zhong, F., Hooda, Y., Hegde, R.S., Keenan, R.J., 2022. Substrate-driven assembly of a translocon for multipass membrane proteins. *Nature* 611, 167–172.
- Szaruga, M., Munteanu, B., Lismont, S., Veugelen, S., Horrè, K., Mercken, M., Saido, T.C., Ryan, N.S., De Vos, T., Savvides, S.N., Gallardo, R., Schymkowitz, J., Rousseau, F., Fox, N.C., Hopf, C., De Strooper, B., Chávez-Gutiérrez, L., 2017. Alzheimer's-Causing mutations shift A $\beta$  length by destabilizing  $\gamma$ -Secretase-A $\beta$ n interactions. *Cell* 170, 443–456.
- Szczepanowska, K., Trifunovic, A., 2022. Mitochondrial matrix proteases: quality control and beyond. *FEBS J.* 289, 7128–7146.
- Tamm, L.K., Hong, H., Liang, B., 2004. Folding and assembly of beta-barrel membrane proteins. *Biochim. Biophys. Acta* 1666, 250–263.
- Tao, Y.X., Conn, P.M., 2014. Chaperoning G protein-coupled receptors: from cell biology to therapeutics. *Endocr. Rev.* 35, 602–647.
- Taylor, D.R., Hooper, N.M., 2006. The prion protein and lipid rafts (review). *Mol. Membr. Biol.* 23, 89–99.
- Teese, M.G., Langosch, D., 2015. Role of GxxxG motifs in transmembrane domain interactions. *Biochemistry* 54, 5125–5135.
- Tomasek, D., Kahne, D., 2021. The assembly of beta-barrel outer membrane proteins. *Curr. Opin. Microbiol.* 60, 16–23.
- Tripathy, M., Srivastava, A., 2023. Lipid packing in biological membranes governs protein localization and membrane permeability. *Biophys. J.* 122, 2727–2743.
- Van Den Berg, B., Clemons, W.J.R., Collinson, I., Modis, Y., Hartmann, E., Harrison, S.C., Rapoport, T.A., 2004. X-ray structure of a protein-conducting channel. *Nature* 427, 36–44.
- Van Der Paal, J., Neyts, E.C., Verlackt, C.C.W., Bogaerts, A., 2016. Effect of lipid peroxidation on membrane permeability of cancer and normal cells subjected to oxidative stress. *Chem. Sci.* 7, 489–498.
- Van Goor, F., Hadida, S., Grootenhuys, P.D., Burton, B., Stack, J.H., Straley, K.S., Decker, C.J., Miller, M., McCartney, J., Olson, E.R., Wine, J.J., Frizzell, R.A., Ashlock, M., Negulescu, P.A., 2011. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. *Proc. Natl. Acad. Sci. U. S. A.* 108, 18843–18848.
- Van Meer, G., Voelker, D.R., Feigenson, G.W., 2008. Membrane lipids: where they are and how they behave. *Nat. Rev. Mol. Cell Biol.* 9, 112–124.

- Vanier, M.T., 2010. Niemann-pick disease type C. *Orphanet J. Rare Dis.* 5, 16.
- Vembar, S.S., Brodsky, J.L., 2008. One step at a time: endoplasmic reticulum-associated degradation. *Nat. Rev. Mol. Cell Biol.* 9, 944–U30.
- Vendruscolo, M., 2022. Lipid homeostasis and its links with protein misfolding diseases. *Front. Mol. Neurosci.* 15.
- Von Heijne, G., 2006. Membrane-protein topology. *Nat. Rev. Mol. Cell Biol.* 7, 909–918.
- Vonheijne, G., 1989. Control of topology and mode of assembly of a polytopic membrane-protein by positively charged residues. *Nature* 341, 456–458.
- Wallin, E., Von Heijne, G., 1998. Genome-wide analysis of integral membrane proteins from eubacterial, archaean, and eukaryotic organisms. *Protein Sci.* 7, 1029–1038.
- Walter, P., Ron, D., 2011. The unfolded protein response: from stress pathway to homeostatic regulation. *Science* 334, 1081–1086.
- Walters, R.F.S., Degrado, W.F., 2006. Helix-packing motifs in membrane proteins. *Proc. Natl. Acad. Sci. U. S. A.* 103, 13658–13663.
- Walther, D.M., Rapaport, D., 2009. Biogenesis of mitochondrial outer membrane proteins. *Biochim. Biophys. Acta Mol. Cell Res.* 1793, 42–51.
- Wang, P., Dalbey, R.E., 2011. Inserting membrane proteins: the YidC/Oxa1/Alb3 machinery in bacteria, mitochondria, and chloroplasts. *Biochim. Biophys. Acta* 1808, 866–875.
- Wang, M., Kaufman, R.J., 2016. Protein misfolding in the endoplasmic reticulum as a conduit to human disease. *Nature* 529, 326–335.
- Wang, Y.J., Di, X.J., Mu, T.W., 2014. Using pharmacological chaperones to restore proteostasis. *Pharmacol. Res.* 83, 3–9.
- Wentink, A., Rosenzweig, R., Kampinga, H., Bukau, B., 2025. Mechanisms and regulation of the Hsp70 chaperone network. *Nat. Rev. Mol. Cell Biol.*
- White, S.H., 2005. How hydrogen bonds shape membrane protein structure. *Adv. Protein Chem.* 72, 157–172.
- White, S.H., Wimley, W.C., 1999. Membrane protein folding and stability: physical principles. *Annu. Rev. Biophys. Biomol. Struct.* 28, 319–365.
- White, E., Mckenna, J., Cavanaugh, A., Breitwieser, G.E., 2009. Pharmacochaperone-mediated rescue of calcium-sensing receptor loss-of-function mutants. *Mol. Endocrinol.* 23, 1115–1123.
- Wiczew, D., Szulc, N., Tarek, M., 2021. Molecular dynamics simulations of the effects of lipid oxidation on the permeability of cell membranes. *Bioelectrochemistry* 141.
- Wijesinghe, W.C.B., Min, D., 2023. Single-molecule force spectroscopy of membrane protein folding. *J. Mol. Biol.* 435.
- Wilkinson, S., 2020. Emerging principles of selective ER autophagy. *J. Mol. Biol.* 432, 185–205.
- Winkhofer, K.F., Tatzelt, J., Haass, C., 2008. The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. *EMBO J.* 27, 336–349.
- Wiseman, R.L., Mesgarzadeh, J.S., Hendershot, L.M., 2022. Reshaping endoplasmic reticulum quality control through the unfolded protein response. *Mol. Cell* 82, 1477–1491.
- Wong-Ekkabut, J., Xu, Z., Triampo, W., Tang, I.M., Tieleman, D.P., Monticelli, L., 2007. Effect of lipid peroxidation on the properties of lipid bilayers: a molecular dynamics study. *Biophys. J.* 93, 4225–4236.
- Wu, J., Ding, W.G., Horie, M., 2016. Molecular pathogenesis of long QT syndrome type 1. *J. Arrhythm* 32, 381–388.
- Wu, H.X., Smalinskaite, L., Hegde, R.S., 2024. EMC rectifies the topology of multipass membrane proteins. *Nat. Struct. Mol. Biol.* 31.
- Wüller, S., Wiesner, B., Löffler, A., Furkert, J., Krause, G., Hermsilla, R., Schaefer, M., Schüle, R., Rosenthal, W., Oksche, A., 2004. Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors. *J. Biol. Chem.* 279, 47254–47263.
- Xie, X., Yu, T., Li, X., Zhang, N., Foster, L.J., Peng, C., Huang, W., He, G., 2023. Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials. *Signal Transduct. Targeted Ther.* 8, 335.
- Xin, J., Yin, K., Li, S., Gu, P., Shao, S., 2025. Exploring the ER channel protein Sec61: recent advances in pathophysiological significance and novel pharmacological inhibitors. *Front. Pharmacol.* 16, 1580086.
- Yamada, S., Funada, T., Shibata, N., Kobayashi, M., Kawai, Y., Tatsuda, E., Furuhashi, A., Uchida, K., 2004. Protein-bound 4-hydroxy-2-hexenal as a marker of oxidized n-3 polyunsaturated fatty acids. *J. Lipid Res.* 45, 626–634.
- Yang, Y., Guo, R., Gaffney, K., Kim, M., Muhammednazaar, S., Tian, W., Wang, B., Liang, J., Hong, H., 2018. Folding-degradation relationship of a membrane protein mediated by the universally conserved ATP-dependent protease FtsH. *J. Am. Chem. Soc.* 140, 4656–4665.
- Yang, Z., Cao, Y., Kong, L., Xi, J., Liu, S., Zhang, J., Cheng, W., 2024. Small molecules as modulators of the proteostasis machinery: implication in cardiovascular diseases. *Eur. J. Med. Chem.* 264, 116030.
- Yau, W.M., Wimley, W.C., Gawrisch, K., White, S.H., 1998. The preference of tryptophan for membrane interfaces. *Biochemistry* 37, 14713–14718.
- Yi, Q.Z., Yao, S.H., Ma, B.Y., Cang, X.H., 2022. The effects of cardiolipin on the structural dynamics of the mitochondrial ADP/ATP carrier in its cytosol-open state. *JLR (J. Lipid Res.)* 63.
- Zhang, M., Chen, T., Lu, X., Lan, X., Chen, Z., Lu, S., 2024. G protein-coupled receptors (GPCRs): advances in structures, mechanisms, and drug discovery. *Signal Transduct. Targeted Ther.* 9, 88.
- Zhao, L., Zhao, J., Zhong, K., Tong, A., Jia, D., 2022. Targeted protein degradation: mechanisms, strategies and application. *Signal Transduct. Targeted Ther.* 7, 113.